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Life is what happens, when all the ‘what if´s’ don´t. 
  

  
ABSTRACT 
Most successful licensed vaccines mediate protection by inducing antibody responses capable 
of protecting the individual from infection or disease. Despite the availability of many 
effective vaccines, we lack knowledge about fundamental aspects of B cell immunity and 
how we respond to complex real-world protein antigens. HIV-1 is a particularly difficult 
vaccine target since it has evolved multiple strategies to evade host antibody responses, such 
as conformational and glycan shielding. A consequence of this effective shielding is that the 
most immunogenic determinants of the envelope glycoprotein (Env) spike are those that the 
virus can readily mutate, which give rise to strain-specific antibodies. The conserved 
determinants of Env, which are targets for broadly neutralizing antibodies, tend to be less 
immunogenic. Another challenge has been the production of recombinant immunogens that 
mimic the functional HIV-1 Env spike but recent developments have improved this situation. 
In this thesis, I studied Env-specific immune responses induced by immunization with 
recombinant Env trimers to broaden our knowledge about B cell responses against this 
complex protein antigen.  
In brief, I investigated basic B cell questions using HIV-1 Env as a model antigen in a series 
of mouse immunogenicity studies. In Paper I, we asked whether or not there is a competition 
between B cells that recognize distal epitopes on HIV-1 Env. The variable region 3 (V3) of 
Env is highly immunogenic. We therefore masked the V3 region with N-linked glycans to 
study if the elicited response would be re-distributed to other more conserved determinants on 
Env. The results indicated that there was no competition between B cells. Instead, we 
observed a total decrease in the antibody responses when the V3 region was shielded. Next, 
in Paper II, we manipulated the naïve B cell repertoire by pre-treating mice with 
recombinant BLyS to rescue additional B cells into the mature naïve B cell pool. The results 
showed that BLyS treatment expanded the naïve B cell population and resulted in improved 
neutralization capacity after Env immunization. In Paper III, we established protocols that 
would allow characterization of vaccine-induced antibody specificities. We describe staining 
protocols for Env-specific memory and germinal center B cells in mice. Finally, in Paper IV, 
we evaluated the effect of chemical cross-linking of HIV-1 Env trimers for the elicited 
antibody response after immunization. The results indicated a Th2 shift in the serum antibody 
isotype response compared to the response elicited in mice immunized with unfixed trimers.  
In conclusion, the purpose of this thesis has been to evaluate strategies to manipulate or re-
direct the antibody response induced by recombinant HIV-1 Env immunogens. The results 
obtained in this thesis gave insights into several fundamental B cell questions of relevance to 
the vaccine field and to our understanding of basic B cell immunology. 
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1 INTRODUCTION 
The purpose of this introduction is to give the reader a broad and sometimes more detailed 
description of information regarding the background of this thesis. The goal is to provide 
background information and a survey of the most relevant literature to make the Results and 
Discussion sections, as well as the enclosed papers, easier to comprehend. 
1.1 B CELL IMMUNOLOGY 
1.1.1 Introduction to the innate and adaptive immune systems 
To combat pathogens, such as viruses, bacteria, parasites and fungi, defense mechanisms 
throughout our body are needed. The immune system serves as our defense against foreign 
antigens. This highly organized machinery of different cell types and organs can be divided 
into two parts, the innate and adaptive immune systems. The receptors responsible for 
recognition of foreign structures expressed by cells of the innate immune system are 
germline-encoded and invariable. While the receptors responsible for recognition of antigen 
in the adaptive immune system, the B and T cell receptors, are highly variable and, in the 
case of B cells, undergo affinity maturation. Furthermore, clonal expansion and generation of 
immune memory are hallmarks of the adaptive immune system, while innate immune 
responses, unless in rare exceptions [1], do not generate memory.  
1.1.1.1 Innate immunity 
The innate immune system is responsible for the initial, rapid response, which takes place 
during the first hours to first couple of days after an infection. The very first line of defense is 
provided by the epithelial cells that surround most of our body surfaces and organs. If this 
barrier fails to block microbes from entering the body, innate immune cells and their products 
will immediately take over. Innate immune cells include phagocytes (i.e. neutrophils, 
monocytes and macrophages), natural killer cells (NK cells) and dendritic cells (DCs). These 
cells play different roles when it comes to host defense. The receptors expressed on innate 
immune cells responsible for alerting the organism to danger are called pattern recognition 
receptors (PRRs) [2]. PRRs recognize pathogen-associated molecular patterns (PAMPs) 
found on microbes. These include Toll-like receptors (TLRs) that bind to bacterial 
endotoxins, single- or double-stranded RNA and unmethylated DNA, and mannose receptors 
binding to glycoproteins or glycolipids with terminal mannose residues (reviewed in [3]). As 
mentioned above, these receptors have limited diversity because they are encoded in the 
germline.  
Neutrophils and monocytes are circulating cells that can be recruited to sites of infection. 
Monocytes that reside in tissues for a long time will differentiate into macrophages. When a 
microbe has broken the epithelial barrier, local macrophages will recognize, bind and 
phagocytose the invading entity. In this process, the cell membrane extends and engulfs the 
foreign antigen bound to surface receptor of the phagocytic cell into intracellular vesicles and 
destroys it via lysosomal enzymes. By producing the cytokines interleukin-1 (IL-1) and 
 2 
tumor necrosis factor alpha (TNFa), macrophages stimulate endothelial cells to express the 
adhesion molecules E-selectin and P-selectin [4, 5], which facilitate recruitment of other 
immune cells to the site of infection.  
Natural killer (NK) cells recognize infected and stressed cells and respond by killing the 
target cell and by producing interferon-g (IFN-g), which in turn activates macrophages. NK 
cells express activating and inhibitory receptors (reviewed in [6]). If inhibitory receptors fail 
to bind to the major histocompatibility complex class I (MHC I) on the target cell, the NK 
cell will become activated and kill the infected cell.  
Dendritic cells (DCs) belong to a group of cells that are especially capable of taking up 
antigen, processing and presenting fragments of it on surface MHC molecules, called antigen-
presenting cells (APCs) [7]. In addition to DCs, macrophages and B cells also have antigen-
presenting capacity and therefore belong to the group of APCs. Each MHC molecule can 
present many different peptides, but only one at the time. There are two different classes of 
MHC molecules, class I and II, which use two different intracellular pathways for antigen 
processing. In the class I pathway (MHC I), endogenously expressed antigens are processed 
and loaded on MHC class I molecules for presentation to CD8+ cytotoxic T cells (CTLs), 
whose function is to kill the infected cell. In B cells and macrophages, the class II pathway is 
responsible for the antigen processing of endocytosed extracellular microbes and antigens. 
These presented peptides are recognized by another type of T cells, the CD4+ Th cells. Due 
to their efficiency in taking up and presenting antigens to cells of the adaptive immunity, DCs 
are considered the most important linker cells between the innate and adaptive immunity [8]. 
1.1.1.2 Adaptive immunity 
The adaptive immune system can be broadly divided into two parts; humoral and cell-
mediated immunity. Compared to innate immunity, the cells of the adaptive immune system 
generally require at least a week to develop the functions required to effectively combat 
invading pathogens.  
Cell-mediated immunity 
T cells are responsible for cell-mediated immunity, whose main function is to clear infections 
caused be intracellular microbes. Different T cell subsets serve different roles in this process; 
CD4+ helper T cells, by activating phagocytes to destroy microbes residing in intracellular 
vesicles, and CD8+ T cells, by killing productively infected cells. The antiviral activity of 
CD8+ T cells is based on target cell killing, which induces apoptosis in the infected target 
cells. There are a number of different subsets that CD4+ helper T cells can differentiate into, 
such as Th1, Th2, Th17, regulatory T cell (Treg), follicular helper T cells (Tfh), as well as 
Th9 and Th22. Depending on the cytokine environment around the CD4+ T cell at the time of 
priming, this will influence transcription factor expression and thereby its differentiation into 
any of the different subsets [9]. CD4+ helper T cells that provide help to B cells during the 
generation of an antibody response, the Tfh cells, will be described in more detail below.  
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Humoral immunity 
Secreted antibodies produced by B cells that have differentiated into plasma cells are the 
main effector molecules in humoral immunity. The B cell receptor repertoire is capable of 
recognizing a large variety of molecules, i.e. proteins, polysaccharides, lipids and lipid toxins 
of which proteins are the most immunogenic (reviewed in [10]). The effector functions of 
antibodies include neutralization and elimination of extracellular pathogens and microbial 
toxins, complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC). 
Antibody responses are either T cell-dependent (TD) or T cell-independent (TI). In the TD 
response, B cells receive signals from cognate CD4+ T helper cells presenting peptides from 
the same antigen on its MHC class II molecules. Antibody responses elicited in TD pathway 
are of higher affinity and have typically undergone isotype switching (see below for more 
details). B cells recognizing polysaccharides, lipids and other non-protein antigens become 
activated in the absence of CD4+ T cell help, which is therefore named TI responses. These 
antibodies produced as part of a TI response have rarely undergone isotype switching and 
little, if any, affinity maturation [10]. Humoral immunity is the main focus of this thesis and 
will therefore be discussed in more detail in the following sections. 
1.1.2 The development of early B cells in the bone marrow 
The various stages of early B cell development take place in the bone marrow (BM) (in 
adults) or in the fetal liver (during embryonic life). B cells originate from hematopoietic stem 
cells (HSC) that differentiate to common lymphocyte progenitors (CLP) [11, 12]. During B 
cell development, the primary immunoglobulin (Ig) diversification takes place. At the stage 
of progenitor (pro) B cells and precursor (pre) B cells, DNA recombination is initiated by the 
first step to assemble gene segments in a stepwise process known as V(D)J recombination to 
generate the functional immunoglobulin/BCR repertoire (this process will be discussed in 
further detail later).   
When the IL-7 receptor starts to be expressed at the CLP stage, it results in the induction of B 
cell development, first via the pro-B cells. In pro-B cells, IL-7 receptors play a central role by 
signaling survival [13]. Other transcription factors that are important for the CLP to pro-B 
cell differentiation include E2A, EBF and Pax5 [14]. V(D)J recombination starts in the pro-B 
cell stage by the rearrangement of DH to JH segments of the Ig heavy chain (IgH). Next, the 
pro-B cell proceeds to the pre-B cell stage where the VH to DJH segment joining takes place. 
When a successful VDJH rearrangement has occurred, a pre-B cell receptor (pre-BCR) starts 
to be expressed on the pre-B cell surface. The pre-BCR contains the IgH and a surrogate light 
chain (SL), which comprises of the proteins Vpre5 and l5. Vpre5 and l5 make up a molecule 
that is structurally similar to the Ig light chain (IgL) [15, 16]. The expression of a pre-BCR 
indicates an important survival step in the early B development. In late pre-B cell stage, the 
IgL rearrangement starts. Gene segments of VL and JL rearrange and replace the SL, which 
results in BCR expression on immature/naïve B cells [17, 18]. There is an extreme turnover 
of B cells during development in the BM. In mice, it has been estimated that 2x107 BCR 
expressing immature B cells are developed daily, but approximately only 10% of those will 
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be selected to the pool of immature/naïve B cells in the periphery [19]. This stringent filter is 
called negative selection, with the purpose to remove self-reactive B cells from the immature 
B cell pool by elimination [20-22], receptor editing [23, 24] or anergy [25, 26]. 
1.1.3 Architecture of secondary lymphoid organs 
Secondary lymphoid organs (SLOs) are different peripheral lymphoid tissues where the 
lymphocytes become activated, which include spleen, lymph nodes (LNs), tonsils, Peyer’s 
patches and mucosa associated lymphoid tissue (MALT). In humoral immunity, these organs 
function as a filtering system where extracellular fluids, such as blood, lymphatic- and tissue 
fluid, are filtered and antigens trapped. SLOs are highly qualified structures to promote 
antigen and cell interactions. Not only because of the capacity to filter and capture antigens, 
their microarchitecture also allows for different compartments where different cell types can 
interact to initiate immune responses and the subsequent fate of each cell type (reviewed in 
[27]). To optimize antigen-capture and presentation, circulating cells leave the current SLO if 
unsuccessful antigen capture appears to recirculate through the body to search for antigens 
elsewhere in other SLOs [28]. The architecture and cells located in these organs differ to 
some extent from each other as well as in respective counterparts in different species. 
1.1.3.1 Spleen and lymph node 
The spleen is the largest SLO in the body and consists of the red and the white pulp. The red 
pulp, which is rich in blood and therefore function as a blood filter by removing foreign 
material [29]. The white and the red pulp is separated by the marginal zone (MZ), which is 
located in the white pulp. Other structures within the white pulp are the follicle (also known 
as the B cell zone) and the periarteriolar lymphoid sheath (PALS).  There are several 
differences in the architecture of the lymph node compare to the spleen [27]. One of them is 
that, in mice, MZ B cells are only thought to be present in the spleen, although a similar 
population recently was found in LN and suggested to represent MZ-like B cells [30]. 
1.1.4 B cell subsets in the periphery 
Apart from the B cells mentioned in previous section, there are a number of other subsets of 
B cells that originate from the pool of IgM-surface expressing mature B cells found 
throughout the body. These B cell populations differ from each other by their distinct 
functions, where they anatomically are located, their expression of surface molecules and 
how they participate in an immune response. The three major subsets of mature B cells found 
in mice are: B-1 cells, MZ B cells and follicular B cells [31]. 
1.1.4.1 B-1 cells 
In addition to B cell development in the bone marrow, which occurs throughout life, a distinct 
subset of B cells develops in the fetal liver and during early life, after which they persist 
throughout life via self-renewal (reviewed in [32]). B-1 cells are the dominating lymphocyte 
populations in pleural and peritoneal cavities. About 30-60% of all lymphocytes in these 
locations are B-1 cells and they respond primarily to non-protein antigens. In SLOs the 
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frequency of these cells is very low, 0.2-1% of all lymphocytes. B-1 cells can be further 
divided into B-1a and B-1b B cells distinguished by the surface expression of CD5. B-1-a 
cells express CD5, whereas B-1b cells do not. B-1a cells produce so called natural antibodies 
present at steady state which are produced in absence of exogenous stimulation. These 
antibodies are characterized as poly-reactive low-affinity antibodies primarily of the IgM 
isotype. B-1 cells are responsible for the early and rapid immune responses against TI 
antigens along with MZ B cells. Instead of requiring help from CD4+ T cells, co-stimulation 
of innate receptors activates the cell, making them a rapid responsive line of defense, within 
the first day of infection proliferate and differentiate into plasmablasts. This capacity of rapid 
response makes the B-1 cells an important compliment to the later arising extra-follicular B-2 
cell responses [33, 34].  
1.1.4.2 B-2 cells 
The other group of mature B cells is the B-2 cells, which encompass follicular B cells and 
MZ B cells. B-2 cells are generated in the BM throughout life.  
Follicular B cells represent the vast majority of B cells in the spleen and LNs, as well as 
among circulating B cells. Follicular B cells comprise up to 80-90% of all B cells in the 
spleen and LNs and thus represent the largest B cell subset. Their name refers to the fact that 
these cells resides in the follicle of lymphoid organs.  
MZ B cells (IgMhiIgDlowCD21hiCD23low) reside in the marginal zone of the spleen, located at 
the border of the red and white pulp. Although MZ B cells are described to be restricted to the 
spleen, a recent study reported nodal MZ B cells in lymph nodes of several mouse strains 
with a phenotype like splenic MZ B cells sharing similar functions and anatomical 
distribution [30]. MZ B cells function as a shuttle for antigen into the lymphoid organs and to 
be the first line of defense against blood-borne antigens. Their specific location helps the MZ 
B cells capture antigen in the MZ [35] and deliver it the follicle to follicular DCs (FDCs), 
also located in the white pulp. This shuttling has been shown to be CXCR5 dependent [36]. 
Together with B-1b cells, MZ B cells play a role in the early and rapid immune response 
against both TD and TI antigens, primarily the later [37]. 
1.1.5 Developing stages of immature/naïve B cells in the periphery 
Immature/naïve B cells exit the BM via the circulation and migrate to the periphery, for 
further differentiation. Transitional B cells are, as the name implies, a transitional stage of B 
cells to differentiate from immature to mature B cells. These cells develop from the B cells 
leaving the BM and migrate to the spleen [38], not LNs [39]. It is unclear why transitional B 
cells cannot populate LNs and differentiate to mature B cells there, although suggestions 
regarding lack of some cell surface receptors and structural differences in that organ might be 
an explanation [38, 39]. The differentiation to mature/naïve B cells is a three-step process 
where B cells undergo the three transitional stages (T1-T3). However, it is discussed if there 
actually exist a third stage (T3) and therefore the transitional B cells sometimes are divided 
into T1 and T2/3. The different transitional B cells are distinguished by differences in surface 
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marker expressions, by T1 (IgMhiIgD-CD21-CD23-AA4.1+) being similar to immature B cell 
phenotype whereas T2 (IgMhiIgD+CD21+CD23+AA4.1+) and T3 (IgM+IgD+CD21+CD23+ 
AA4.1+) becomes more and more similar to the mature B cell phenotype 
(IgM+IgDhiCD21+CD23+AA4.1-) [38, 40-42].  
Like the negative selection of self-reactive B cells removes these from the B cell pool during 
development in the BM, a similar checkpoint takes place in the spleen among transitional B 
cells. In order to be able to differentiate into mature naïve B cells and MZ B cells, the 
transitional B cells needs to receive a survival signal [38]. A highly potent cytokine to 
mediate survival signals to several B cell subsets is called B lymphocyte stimulator (BLyS), 
also known as BAFF [43-46]. BLyS belongs to the TNF family and mediates its effect via 
binding to three different receptors expressed on B cells; BLyS receptor 3 (BR3; also known 
as BAFF-R), BCMA and TACI [43, 47-49]. Although BLyS can bind all three receptors, it is 
through binding to BR3 that it has been shown to have strongest association with pro-survival 
effect on transitional, mature/naïve and GC B cells [50]. It is worth mentioning that there is a 
close homologue to BLyS called APRIL, which binds the same receptors as BLyS except 
BR3 and does not have the same B cell survival effect as BLyS [51, 52]. Both deficiency and 
overexpression of BLyS impacts the final mature naïve B cell pool. In mice and humans 
deficient in either BLyS or BR3 shows compromised transitional and mature naïve B cell 
pools [53, 54], whereas hyperplasia and autoimmunity (at least signs of it) appears during 
overexpression of BLyS [43, 55].  
1.1.5.1 Extra-follicular B cell responses 
Mature/naïve B cells need two signals to become activated. The activation takes place at the 
T- and B cell boarder. It starts with the capturing of the cognate antigen in the B cell zone of 
SLOs. The first signal appears when a B cell binds the antigen to the BCR, internalize it, 
degrades it and finally express a peptide bound on the MHCII on its cell surface. If the B cell 
interacts with a CD4+ T cell that recognize the peptide expressed by binding to it with its T 
cell receptor (TCR), the first part of the second activation signal is received by the B cell. The 
interaction between CD40 ligand (CD40L) on T cells and CD40 on B cells completes the 
second activation signal in B cells, which also signals survival and proliferation [56]. To 
make it possible for the two types of lymphocytes to meet and interact, chemokines and 
chemokine receptors are essential for both cell types.  
After encounter of cognate antigen and receiving activation signals from T cells, mature B 
cells become activated and can undertake two distinct pathways. Either they enter the follicle 
or differentiate into short-lived plasma cells (PCs) outside the follicle. The short-lived PCs 
leave the SLOs and produce low affinity IgM antibodies, but reports have also shown 
secretion of class-switched antibodies [57-59]. Although some class switching appears 
independently of GC reaction, the generated antibodies seem not to have undergone somatic 
hypermutation (SHM) or improved its antigen-affinity [60, 61]. These antibodies are the first 
antibody defense against TD antigens and can be measured within a few days after infection. 
It is not clear what decides the fate of activated B cells. It appears that B cells with higher 
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affinity for the cognate antigen primarily differentiate into short-lived PCs, whereas B cells 
expressing BCR with lower affinity (but still above a certain threshold) will enter germinal 
center (GC) reactions [62, 63]. 
Figure 1. Overview of B cell development in BM and periphery. V(D)J recombination takes place during B cell 
development in the BM at several separate B cell differentiation stages. In the periphery, the immature B cell 
undergoes maturation by going through transitional B cell stages. B cells can then either differentiate to MZ B 
cells or follicular B cells. After activation, follicular B cells differentiate into extra-follicular plasma cells or 
enter the GC reaction, where the BCR undergoes SHM and class-switching. GC B cells that are positively 
selected after expansion and affinity maturation in the GC differentiate into PCs or memory B cells. Illustration 
by Martina Soldemo. 
 
1.1.6 Germinal center reaction and affinity maturation 
GCs are specialized structures in the follicle where activated B cells undergo somatic 
hypermutation (SHM) to increase the affinity to the cognate antigen as well as and class 
switching to change effector function of the antibody. These processes will be described in 
more details in section 1.1.8. Depending on the antigen, GCs persist between weeks to 
months [64-67]. Within in the follicle, GC B cells go through different stages in sub-
structures, called light and dark zones (LZ and DZ). These zones are separated from each 
other and play different roles [68]. In the DZ, where GC B cells first end up after entering the 
GC, the GC B cells are called centroblasts. As centroblasts, they proliferate extensively and 
express CXCR4. It is in the DZ where the affinity mutation occurs of the BCRs. This process 
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requires that the antibody sequences undergo SHM and will be presented in more details 
further down The BCR may also undergo class-switching (see 1.1.8 for more details) to 
convert the constant region from IgM to any of the other subclasses. After this, the GC B 
cells entering the LZ and are now called centrocytes and express CXCR5. In the LZ, the 
FDCs are localized [69]. FDCs are the cell type that has antigen bound to its dendrites in 
order to present them to B cells [70]. They can receive antigens from MZ B cells that actively 
shuttle between the MZ and the GC. The surface immune complexes bind the antigens, which 
are later delivered to the FDCs [71]. Other factors affecting a functional GC reaction is the 
cytokine IL-21 produced by Tfhs, by both regulating differentiation and proliferation of GC 
B cells and by regulating Bcl6 expression [72, 73]. The importance of Bcl6 in GC formations 
has been shown by impairment of its formation, when the Bcl6 gene has been disrupted [74]. 
In the LZ, the mutated BCR is tested with help of the FDCs. From here, the GC B cell has 
two fates; if the BCR has reduced capacity to bind the antigen, or if the BCR has acquired 
self-reactivity, the cell will undergo apoptosis [71] and thereby be deleted from the B cell 
pool. But if the BCR has gained affinity to the antigen, the GC B cell will be selected to 
survive [75] and can leave the GC as plasmablasts (later becomes PCs) or memory B cells. 
The underlying mechanism for the decision of long-lived PCs or memory B cells is still not 
clear, but it appears that long-lived PCs to a larger extent are selected for higher affinity 
compared to memory B cells [76]. A recent study, suggested that a temporal switch in the GC 
could be the reason for the choice of becoming a memory B cell or a long-lived PC. The 
indication is that memory B cells are generated during early GC, whereas long-lived PCs are 
generated late during the GC response [77]. 
1.1.6.1 Memory B cell differentiation 
In contrast to human memory B cells, there are few commonly accepted markers for memory 
B cells in mice. The marker most frequently used is CD38, which is only expressed on 
follicular B cells and memory B cells. As follicular B cells belong to the naïve pool of B 
cells, hence IgD has been used to distinguish naïve B cells from memory B cells [65, 78]. 
Some years ago, a number of additional memory B cell markers was suggested, which were 
highly expressed on memory B cells but not on naïve B cells. Different combinations of the 
markers PD-L2, CD80 and CD71 were shown to make up five, suggested, different subsets of 
memory B cells [79-81]. It is still not known though, whether these memory B cells actually 
are different memory B cell subsets or just phenotypic differences indicating developing 
stages in memory B cells. 
Memory B cells can also be generated on the outside of the GC [82]. In some settings, these 
cells can be IgG switched and generated independent of a GC reaction or Tfh help [83, 84]. 
These memory B cells are similar to IgM memory B cells when comparing the SHM level in 
the antibody genes [85]. 
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1.1.6.2 The generation of long-lived PCs 
The process leading to the final differentiation to antibody-secreting PCs depends on several 
changes in gene expressions. The main genes involved are B lymphocyte induced maturation 
protein 1 (Blimp-1), Xbp-1, Pax5 and Bcl6. Blimp-1 is involved in regulating many of these 
important genes [86], hence having a central role for the generation of PCs. The expression of 
Xbp-1 is required for the unfolded protein response, a process that is important in PCs in 
order to handle the stress associated with the large production, folding and secretion of Igs. 
Blimp-1 is the protein that has been identified to ensure expression of Xbp-1 in PCs [87-90]. 
Other important genes that Blimp-1 controls by repression are Pax5, which is required to 
retain B cell identity, and Bcl6, which is required for B cell proliferation, both of which are 
not desired during PC differentiation and survival [91]. Interferon regulatory factor-4 (IRF4) 
also has an essential role in PC formation. IRF4 is induced by Xbp-1, which increase its 
expression after influence of Blimp-1 as described above [92, 93].  
Before PCs are fully differentiated, but after they have gained the ability to secrete antibodies 
they are called plasmablasts. PCs and plasmablasts differ in several distinct ways. The main 
differences are that plasmablasts are migratory, they proliferate and they express MHCs on 
the cell surface. When it comes to the expression of chemokine receptors, plasmablasts also 
differ from GC B cells. Both CXCR5 and CCR7 are down-regulated, allowing plasmablasts 
to leave the GC [94-96]. It has been suggested that plasmablasts need to be migratory in order 
to reach special survival niches [97]. Long-lived PCs need survival signals in these 
specialized niches. The factors providing these signals have been reported to be APRIL, IL-6 
and CXCL12, which are produced by eosinophils, stroma cells and megakaryocytes [98-100]. 
1.1.7 The role of memory B cells and long-lived plasma cells for long-term 
immunity 
Once a memory B cell re-encounters its cognate antigen it can re-enter the GC reaction. This, 
so called, secondary antibody response differs from primary responses in three ways; (i) the 
response is more rapid, (ii) the IgG, IgA or IgE isotypes are more common than IgM, and (iii) 
the generated antibodies are of higher affinity [101]. Memory B cells seem to be able to 
persist without antigen [102, 103]. Expression of the transcription factor Bach2 differs among 
B cell subsets. In engineered mice (having naïve B cells expressing IgG1), IgG1 memory B 
cells express lower levels of Bach2 than naïve B cells, either expressing IgM or IgG1. The 
lower levels in IgG1 memory B cells correlated with the tendency of favoring PCs 
differentiation instead of re-enter the GC [104]. IgM memory B cells was not studied, but it 
would be interesting to evaluate if there is a mechanism behind a memory B cell’s “choice” 
of re-entering the GC for additional rounds of SHM. Another study indicated that switched 
memory B cells tend to differentiate into plasmablasts rather than entering reformed GCs 
[105], but it remains unknown if IgM memory B cells are favored over switched memory B 
cells when both are present outside the GC. 
As little as 10% of PCs generated after an acute infection, are estimated to become long-lived 
PCs. These PCs are then the main source of secreted antibodies that generates protection in 
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humoral memory [106]. The best example of the duration by which long-lived PCs can 
survive in the BM is serological studies on vaccine-induced antibodies in serum. For some 
vaccines, PCs can be as long-lived as the host [107].  
1.1.8 Genetics and diverse repertoire of the immunoglobulin loci 
To be able to recognize all possible antigens, the immune system has developed a 
combinatorial mechanism to produce a highly diverse antibody repertoire [108]. The Ig genes 
are composed of separate DNA segments, which recombine in different combinations to form 
antibodies with different specificities. Antibodies are glycoproteins and are found as either 
membrane bound (referred to as the BCR or membrane bound antibody) or in secreted forms 
(soluble antibody). Every antibody is composed of four polypeptides from two identical 
heavy (IgH) chains, expressed from the IgH locus, and two identical light (IgL) chains, 
expressed from either the Igκ or Igλ loci. Each Ig chain consists of one variable and one 
constant domain. The variable domain of IgH is encoded by three gene segments, the variable 
(V), diversity (D) and joining (J) segments. The variable domain of IgL is only encoded by 
two gene segments, the V and J segments. The variable domain of the heavy (VH) and light 
(VL) chains are composed of three hypervariable regions termed complementarity-
determining regions 1-3 (CDR1-3), and four less variable framework regions 1-4 (FR1-4). 
The most variable region is the CDR3, where the largest part of the interactions with the 
antigen occur for most antibodies. The genes for the constant regions of IgH are designated µ, 
d, g, e, and α, which after class-switching gives rise to IgM, IgD, IgG, IgE and IgA antibody 
subclasses, respectively [108]. Class-switching is affected by several cytokines; IFNg induces 
a switch to IgG2a, IL-4 to IgG1 and IgE, and TGFb to IgG2b and IgA [109]. 
Figure 2. A schematic of the antibody genetics. Illustration by Martina Soldemo. 
 
1.1.8.1 V(D)J recombination 
V(D)J recombination is a controlled stepwise process. D to J recombination always precedes 
V to DJ recombination on the heavy chain and V(D)J recombination occurs first on IgH 
followed by the IgL. The V, D and J gene segments are flanked by highly conserved 
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recombination signal sequences (RSS) (reviewed in [110]). There are two versions of RSSs; 
the heptamer (5’-CACAGTG-3’) and the nonamer (5’-ACAAAAACC-3’) sequences 
separated by a less conserved spacer sequence. The DNA spacer sequence is either 12 or 23 
base pair in length. To enable successful recombination between correct V gene segments the 
RSS plays an essential role. Efficient recombination can only occur between one 12RSS and 
one 23RSS, referring to the “12/23 rule”. To make “12/23 rule” work, all variable gene 
segments of the same type, e.g. V, D or J, are flanked by one type of signal making only the 
joining of D-J and V-DJ possible, but not V-J joining [110, 111].  
Initiation of V(D)J recombination starts with the lymphocyte-specific protein recombination-
activating gene 1 and 2 (RAG1/RAG2) binding to the RSS flanking the variable gene 
segments. The RAGs bring the gene segments that will be recombined together via the RSS 
with assistance of the DNA-binding proteins HMG1 and HMG2 [112]. This complex creates 
a single-stranded nick between the heptamer and the coding gene segment generating a free 
3’-hydroxyl (OH) group. A double-stranded break is made when the 3’-OH group links 
together with the opposing phosphodiester bond, creating a hairpin of the DNA at the end of 
the gene segment and a blunt-end at the RSS motif. To protect the RSS from degradation, 
RAGs remains bound to the motif as a post-cleavage complex [112].  
The gene segments are brought together via the DNA double-strand break repair pathway, 
non-homologous end joining (NHEJ), to form a functional exon. The NHEJ proteins involved 
in this pathway are a heterodimer of Ku70 and Ku80 (Ku), Artemis, DNA-PKcs, and a dimer 
of DNA ligase/XRCC4 [113]. The RSSs are joined together to create a closed circle DNA, a 
signal joint (SJ), that place no further role in the recombination process. The hairpins at the 
end of the coding sequence are then cleaved with help of a complex of Artemis and DNA-
PKcs. This follows the binding of Ku to DNA-PKcs in order to protect the broken DNA ends 
(reviewed in [114]). 
An additional enzyme, terminal deoxynucleotidyltransferase (TdT), adds random non-
templated nucleotides (N-nucleotides) to the 3’ overhang (at the junctions between the V, D 
and J segments) to further increase the diversity of the variable region [110]. The addition of 
N-nucleotides makes all antibodies unique. The other enzymes in the complex will ligate 
together the two ends of the gene segments completing the recombination process resulting in 
a coding joint. After a functional VH has been formed it is fused to a C region through 
alternative RNA splicing [108]. The light chain then pairs with the matching heavy chain in 
each B cell to form the functional BCR.  
The recombination of heavy and light chain V gene segments takes place at separate stages 
during B cell development. DH-JH and VH-DJH recombination occurs prior to VL-JL 
recombination. At the pre-pro-B cell and pro-B cell stage heavy chain recombination takes 
place whereas the light chain recombination takes place at pre-B cell prior to immature B cell 
stage. 
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As there are two alleles for each IgH chain locus, the immune system has evolved a 
mechanism to avoid bi-specificity of the B cell clone, the process of allelic exclusion. It is 
controlled that each B cell have one productive V(D)J IgH allele and one DJH intermediate 
allele. The DJH intermediate allele will act as a back-up if the first V(D)J IgH is non-
productive after junctional diversity (described in next section). If this occurs, the DJH 
intermediate will undergo joining of VH to DJH, resulting in a B cell containing one 
productive and one non-productive V(D)J IgH (reviewed in [115]). The allelic exclusion is 
controlled to some extent by the SL. As the SL binds to IgH and forms the pre-BCR, this 
leads to down-regulation of the expression and activities of enzymes involved in IgH gene 
rearrangement [116]. 
1.1.8.2 Combinational and junctional diversity due to V(D)J recombination 
Because of the large number of ways in which the Ig gene segments can be rearranged, many 
different antibodies can be produced. It is estimated that approximately 106-108 different 
antibody combinations are possible through V(D)J recombination and is therefore referred to 
as combinatorial diversification. In addition to the combinatorial diversity, junctional 
diversity also contributes to increase the antibody diversity via insertion of non-templated 
nucleotides between the V, D and J segment junctions as described above. In addition to the 
diversity obtained after V(D)J recombination, junctional diversity is estimated to increases 
the diversification up to 1016 unique antibody specificities [108]. However, some of these 
may not result in functional antibodies. 
1.1.8.3 Somatic hypermutation 
To further diversify and increase the affinity for the cognate antigen, mutations can also be 
introduced through the process of SHM. Mutations are randomly introduced in the antibody 
genes and are mainly found in the CDR regions of IgH and IgL V genes [117]. This process 
takes place in the GC [118]. The reason for this is that the CDRs are the regions on the 
antibody that form most of the contact with the antigen whereas FRs are important for the 
structural integrity of the antibody [119]. CDRs were also shown to contain more so called 
hotspots for activation-induced cytidine deaminase (AID) than other parts of the V region 
[120]. These hotspots are characterized by a DGYW motif [121]. SHM is initiated by a small 
protein referred to AID [122], which deaminates cytidines (C) to uridines (U) in single 
stranded DNA (ssDNA) [123-125]. Two different repair pathways will follow to induce 
mutations, the base excision repair (BER) or mismatch repair (MMR) systems.  
The BER repair system starts by removing the U generated by AID deamination, leaving an 
abasic site. The enzyme responsible for this is uracil N-glycosylase (UNG). AP endonuclease 
will follow and cleave the DNA backbone to create a nick at the abasic site, which will be 
processed into a single-nucleotide gap. The gap will, in turn, be filled by help from DNA 
polymerase. DNA ligase 1 or 3 then takes over to seal the nick (reviewed in [117]). 
The MMR pathway normally works by maintaining genomic integrity via elimination of 
mutations that arise spontaneously. During SHM, the MMR pathway will contribute to the 
  13 
mutation. A heterodimer of MSH2 and MSH6 will start the process by recognizing the 
mismatch, followed by exonuclease-1 (Exo1), which removes DNA that surrounds the 
mismatch. DNA polymerase then fills the gap and DNA ligase 1 seals the nick (reviewed in 
[117]). 
1.1.8.4 Class-switch recombination 
Class-switch recombination (CSR) affects the constant region of IgH by introduction of 
double-strand-breaks (DSB), resulting in a switch of the effector function of the antibody. 
This process is not concentrated only to GCs, thus it can occur both inside as well as outside 
of the GC [126]. AID also plays a major role in CSR. The hotspots for AID are here located 
in the switch (S) regions, which are long repetitive, non-coding regions. Palindromic variant 
(AGCT) of DGYW can be found on the complementary strand making it possible for DSB 
[117]. Each Ig class (Cg, Ce and Ca) has its own S region (Sg, Se and Sa). AID starts the 
CSR by introducing a C:T mismatch in the S region located downstream of CH genes.  
After the initiation of C:T mismatch, DSB are introduced by BER and MMR pathways. The 
DSBs undergoes end-joining via C-NHEJ pathway (described in more details in previuos 
section) when Ku70 and Ku80 have bound to the DSBs. The binding to the DSBs promotes 
end ligations of XRCC4/ligase 4 (Lig4). This end-joining brings the S regions together and 
completes the CSR process (reviewed in [117]).  
Different Ig isotypes play different roles in the immune system to eliminate invading 
pathogens; IgG works through endocytosis of antibody-coated antigens, IgE are involved in 
allergic reactions by triggering mast cells to degranulate and IgA works at mucosal surfaces 
to eliminate pathogens breaking the mucosal barrier [127-129]. 
1.2 VACCINES 
1.2.1 General functions of vaccines and the role of B cell induced responses 
The goal of vaccinations is to induce long-lasting immunity consisting of both PCs and 
memory B cells specific to the pathogen in question. Memory B cells are required to generate 
a rapid and protective recall response to antigen re-encounter and long-lived PCs are needed 
to provide first line defense in the form of secreted antibodies [130]. Vaccines are one of the 
most important medical innovations of public health to reduce morbidity and mortality to 
infectious diseases. “Herd immunity” is a term used to describe how a large proportion of a 
population needs to be vaccinated in order to protect the few that are not or cannot be 
vaccinated for various reasons. However, it is important to keep in mind that different 
vaccines require different proportion thresholds of vaccinated individuals in a society to 
create and maintain herd immunity [131]. 
The correlates of vaccine-induced immunity are mostly by antigen-specific IgG serum 
antibodies. For most vaccines, a correlation is also seen with mucosal IgG antibodies. A few 
vaccines also show correlation with mucosal IgA antibodies [130]. When it comes to vaccine-
 14 
induced T cell immunity, only one vaccine has shown T cells as the sole cause of protection. 
For tuberculosis, the BCG vaccine has a strong correlation of CD4+ T cells based immunity 
(summarized in [132]). Antibodies produced by long-lived PCs in the BM can be life-long, 
depending on the vaccine [91, 130]. When half-life of circulating antibodies in vaccinated 
individuals was tested it surprisingly showed that live-attenuated vaccines had an incredible 
long half-life. Measles, mumps and rubella vaccines were estimated to have half-lives of 
3014 years, 542 years and 114 years, respectively. Vaccines based on bacterial toxins for 
tetanus and diphtheria showed, on the other hand, much shorter half-lives of 11 years and 19 
years, respectively [133]. Memory B cells are the other arm of humoral immunity with an 
important impact on vaccine efficacy. In contrast to antibody-secreting cells, the PCs 
responsible for antibody titers in serum, memory B cells do not secrete any antibody. 
However, as they have gone through SHM, or multiple rounds of mutation, and express 
BCRs of high affinity for the vaccine antigen, they are capable of responding fast to a 
secondary encounter with the antigen [134, 135]. Whether memory B cells are important for 
maintaining serological titers by continuous replenishment of the PC pool is a long-standing 
question that awaits further and more definitive studies [133].  
1.2.2 Different types of vaccines 
There are several types of vaccines, depending on when they were developed and what 
pathogen they were designed to protect against.  
Live, attenuated vaccines consist of attenuated forms of the pathogenic virus or bacteria, 
which are able to replicate weakly in the recipient and can therefore cause disease in persons 
with intact immune systems. The advantages of using live attenuated vaccines are that they 
are less costly, the immune response mimics natural infection and it is usually sufficient with 
a single dose to stimulate long-lived responses. Examples of this type of vaccine are the 
measles, mumps, rubella, varicella and tuberculosis (BCG) vaccines. 
Inactivated vaccines use killed pathogens that are unable to replicate in the host. These 
vaccines consist of whole organisms that have been treated with either heat or chemicals to 
become inactivated. By inactivating the pathogen, the vaccine reaches a higher safety level 
and can therefore be administered to immunodeficient people, pregnant women and small 
children. The disadvantages, on the other hand, are the requirement of several immunizations 
and that the addition of an adjuvant (see next section for more details) is often needed. 
Examples of inactivated based vaccines are the cholera, hepatitis A and pertussis vaccines.  
Toxoid vaccines are used when the main cause of illness is a bacterial toxin. The toxins are 
inactivated by formalin treatment. These “detoxified” toxins, called toxoids, are safe for 
usage in vaccines. Examples of vaccines based on bacterial toxins are diphtheria and tetanus. 
Subunit vaccines are based on the antigens of a pathogen that best stimulate the immune 
system. These vaccines can contain anything from 1 to 20 or more different antigens. Using 
subunit vaccines lower the risk of adverse reactions since only the most essential antigens are 
  15 
used. Examples of subunit vaccines are the seasonal influenza virus, hepatitis B and human 
papilloma virus vaccines. 
Conjugated vaccines are used for immature immune systems of infants and younger children 
who cannot recognize the polysaccharide coating on bacteria. This has been solved by 
conjugating toxoids to the polysaccharide. The toxoid is recognized by the immune system 
and thereby helps the immune response to be directed against the conjugated polysaccharide.  
[136, 137]. Examples of conjugated vaccines are haemophilus influenza type B (Hib) and 
meningococcal infection. 
1.2.3 Vaccines against variable pathogens 
Currently available vaccines have largely been developed empirically, which means that the 
causative agent of an infectious disease has been isolated, followed by inactivation if needed 
and in vivo testing [138]. This strategy has been successful for a long time, but has given us 
limited understanding on how these vaccines works to activate the immune system and which 
specific epitopes are targeted to mediate the protective response. When comparing the 
antigenic variation among pathogens for which successful vaccines have been developed and 
those for which vaccines are still lacking, it is clear that the pathogens for which we have 
vaccines show no or limited variability over time [138]. Highly variable pathogens are 
considerably more challenging for vaccine development such as human immunodeficient 
virus type 1(HIV-1), which displays extreme antigenic variability. However, despite the 
enormous variability of circulating HIV-1 variants, some determinants are conserved 
suggesting that these could be targeted to induce cross-reactive antibodies [139].  Such efforts 
are actively pursued but have been shown to present major challenges. The influenza virus 
has an antigenic variability on a yearly basis, which has been solved by developing seasonal 
vaccines [138].  
1.2.4 Adjuvants 
The word adjuvant comes from the Latin word “adjuvare” which means “to help” or “to 
enhance”. A vaccine adjuvant is a component that increases the specific immune response to 
an antigen. Adjuvants are necessary in vaccines where non-living pathogens are used, to help 
triggering the immune response. Live attenuated vaccines mimic natural infection and, hence, 
are capable of triggering a strong immune response by themselves. More than one adjuvant 
may be present in the final vaccine. Although a variety of candidate adjuvants have been 
evaluated in the past few decades, only a limited number of vaccine adjuvants are currently 
available and approved to be used in humans [140]. The mode of action for most licensed 
adjuvants is not fully understood, but in general, the goals of adjuvants are to increase antigen 
uptake, induce danger signals and to recruit the right type of immune cells to the site of 
injection [141, 142]. 
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1.3 HIV-1 AS AN ANTIBODY VACCINE TARGET 
1.3.1 Introduction to HIV-1 structure and function 
Human immunodeficiency virus type-1 (HIV-1) was first discovered in 1981 and has since 
then become one of the most studied viruses. HIV-1 is a lentivirus, a member of the 
retrovirus group, and infects human cells expressing the surface CD4 molecule and one of 
two co-receptors (CXCR4 and CCR5), usually CCR5, such as CD4+ T cells, macrophages 
and dendritic cells [143, 144]. The only viral protein exposed on the surface of the virus is the 
envelope (Env) glycoprotein, which is synthesized as a gp160 precursor before the processing 
into a trimer containing heterodimers of gp120 and gp41 subunits. During the processing, 
gp160 undergoes several events in the endoplasmic reticulum (ER) including signal peptide 
cleavage, folding, trimerization and extensive glycosylation [145]. To become a native trimer, 
further events takes place within the host cell. The gp160 is transported to the Golgi 
apparatus where it becomes cleaved with help from furin-like proteases into non-covalently 
linked gp120 and gp41 subunits [146]. Glycosylation of asparagine (N) residues to attach the 
precursor glycan is performed by glycosyl-transferases in the ER, which are then processed 
into high-mannose, hybrid or complex glycans in the Golgi apparatus [146]. After assembly 
of the mature gp120 and gp41 heterodimers, the functional trimer has been formed on the 
plasma cell membrane of the infected cells for incorporation into budding virions. Compared 
to influenza virus, HIV-1 incorporates very few Env spikes in its membrane. It is estimated 
that on average only 14 functional Env spike proteins are present on each HIV-1 particle 
along with numerous non-functional spikes [147, 148]. 
HIV-1 entry can be described as a three-step process. The first step, after the virus has 
attached to the target cell surface via various adhesion molecules, is when the primary host 
cell receptor CD4 binds to the CD4 binding-site (CD4bs) of the HIV-1 Env spike [149, 150]. 
Conformational changes in the Env structure follows this primary binding to allow Env spike 
binding to the co-receptor (CCR5 or CXCR4) on the host cell [151] mediated by the co-
receptor-binding site (CoRbs). This interaction leads to further conformational changes in the 
Env spike resulting in that the fusion peptide located on the gp41 subunit binds and penetrates 
the host plasma membrane [152, 153], the third step of the entry process. Once this has 
occurred, the virus enters the host cells’ cytoplasm where it uncoats and delivers its RNA 
content (reviewed in [154]). The RNA will then be reversed transcribed by the error-prone 
reverse transcriptase (RT) to become double stranded DNA, known as a provirus. The 
provirus is then interacting with HIV-1 integrase and other components to generate a pre-
integration complex [155]. This pre-integration complex is then transported to the nucleus of 
the infected cell, where it integrates with the host DNA [156, 157]. By having become 
integrated to the host genome, the virus can become latent and survive in the host cell [158] 
Although the number of new HIV-1 infections have been declining the last two decades, 
around 1.8 million new HIV-1 cases were estimated worldwide by UNAIDS in 2016. The 
number of people living with HIV-1 and the number of acquired immune deficiency 
syndrome (AIDS)-related deaths in 2016 was estimated to 36.7 and 1 million, respectively 
  17 
(aidsinfo.unaids.org). The prevention programs have been important locally to spread light on 
this epidemic, but a vaccine is needed to control this global HIV-1 epidemic.  
1.3.2 Mechanisms to evade the immune system 
HIV-1 has unique properties making it a difficult target to develop an efficient prophylactic 
vaccine against. The virus has evolved several immune escape mechanisms summarized 
below. 
1.3.2.1 Mutation rate 
The extremely high mutation rate of HIV-1 has created a constant race between the human 
immune system and the virus itself, where the virus is several steps ahead the immune 
system. As a result, the elicited anti-Env antibodies are only able to neutralize virus that was 
generated months earlier and not concurrent circulating variants [159-161]. The error-prone 
RT is the major cause for the rapid genetic variability exhibit in HIV-1. It has been estimated 
that it introduces on average 0.2 mutations per viral genome at each replication cycle [162, 
163]. This leads to an incredible high number of 1010 new virions in an HIV-1 infected 
individual every day [164]. 
1.3.2.2 Glycan masking 
Another efficient strategy to avoid recognition of conserved epitopes by the immune system 
in the host, is to cover most of its surface in glycans. As a result, HIV-1 Env is a highly 
glycosylated protein, with approximately 50% of the gp120 molecular weight comprising 
glycans. Each gp120 has approximately 25 N-linked glycosylation sites, which makes it one 
of the most glycosylated viral proteins known [165]. These glycans are host-derived and are 
large, complex carbohydrate structures that effectively shield vulnerable epitopes on Env, 
hence referred to as the glycan shield [166, 167]. Some chronically infected HIV-1 patients 
are capable of generating antibodies that can penetrate this tight glycan shield and bind to 
otherwise hidden Env protein structures. These antibodies show features that are uncommon 
in healthy individuals, such as a very high level of SHM, long HCDR3, N-glycan reactivity 
and self-reactivity [168-171]. By removing some of these glycosylation sites it has been 
shown to result in an increase in neutralization sensibility of the virus [172]. 
1.3.2.3 Conformational masking 
To protect essential structures involved in binding to the host cell, the HIV-1 virus has 
evolved a mechanism known as conformational masking to escape recognition of neutralizing 
antibodies. The CD4bs and CoRbs are protected by glycans and variable regions as well as 
the natural flexibility of Env. Both the CD4bs and the CoRbs are protected by conformational 
masking [173], minimizing the time when antibodies can reach and bind these structures.  
1.3.2.4 Low Env spike density 
As mentioned previously, HIV-1 incorporates surprisingly few Env proteins on its surface. 
This low number of available Env proteins could be an escape strategy to prevent bivalent 
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binding (i.e. when an antibody binds with both arms to an antigen or several antigens) [174]. 
Clearly, this spike density is sufficient for the virus to effectively infect cells so it is likely 
that the virus has evolved to require as few spikes as possible to minimize the exposure of 
immunogenic determinants to the immune system. 
1.3.2.5 Expression of non-functional Env on the viral surface 
HIV-1 exposes a mixture of Env variants on its surface. Along with the functional trimeric 
Env spike other forms of trimers also exist, such as those that have shed gp120, leaving only 
gp41 stumps and uncleaved non-functional Env spikes [147, 175]. In addition, a considerable 
amount of soluble gp120 is present in circulation, acting as an efficient immune decoy. 
Antibodies against these non-functional forms of Env dominate the total antibody response 
during HIV-1 infection [176], as well as in immunization studies [177], because they expose 
structural elements that are highly immunogenic [147].  
1.3.3 Types of antibodies induced during HIV-1 infection 
Under normal circumstances, highly poly- and autoreactive antibodies are removed from the 
B cell pool during B cell development [178]. During HIV-1 infection the situation is different 
as peripheral selection check-points are perturbed resulting in HIV-1 Env antibodies that are 
frequently poly-reactive and bind non-HIV antigens [179, 180]. During the preparation of this 
thesis, we wrote a review article about this subject (Soldemo and Karlsson Hedestam, 
Frontiers of Immunology (2017). https://doi.org/10.3389/fimmu.2017.01057), which covered 
some of the points discussed below. 
1.3.3.1 B cell dysfunction in HIV-I infected individuals 
When comparing antibodies induced during chronic HIV-1 infection and by subunit 
vaccination, it is important to bear in mind that the immune system in chronically HIV-1 
infected individuals differ in many ways from that of healthy individuals. Prolonged antigen 
exposure, but also continuously antigen variability during chronic HIV-1 infection differs 
remarkably from an immunization situation where a relatively short immunization schedule is 
used in combination with, in most cases, an invariant Env protein.  
During chronic HIV-1 infection, several imbalances in B cell subsets develop, affecting the 
capacity of chronically infected individuals to respond to vaccination and handle co-
infections [181-185]. Hypergammaglobulinemia and loss of B cell memory are hallmarks of 
these humoral immunity alterations [186, 187]. Dysregulation of B cells is apparent relatively 
early after HIV-1 infection and worsens during disease progression. Early introduction of 
antiretroviral therapy to dampen active viremia has positive effects on preserving B cell 
subsets [188]. Dysregulated B cell subsets and functions are also observed in individuals 
repeatedly exposed to malaria [187]. Thus, B cell alterations in both HIV-1 and malaria-
infected subjects is likely a consequence of prolonged inflammatory responses that occur 
under these conditions, rather than caused by direct pathogen-B cell interactions. The specific 
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B cell alterations described in chronically HIV-1-infected individuals include effects on both 
antigen-inexperienced cells and antigen-experienced cells as discussed below. 
Antigen-inexperienced cells. HIV-1-infected individuals display increased frequencies of 
circulating immature transitional B cells [189]. As transitional B cells display increased 
sensitivity to spontaneous apoptosis, this may lead to a decreased pool of mature naïve B 
cells [190, 191]. Altered migratory capacity of immature transitional B cells was also 
observed, which could affect the distribution of these cells between blood and SLOs in 
HIV-1 infected individuals [192]. Further, as previously described, peripheral B cell 
selection is regulated by BLyS. The BLyS levels are increased during HIV-1 infection and 
may result from sustained IFN type 1 responses due to chronic viremia. A potential 
consequence of increased BLyS levels is that the threshold for B cell selection is altered, 
which may promote survival of B cells that otherwise would be subject to negative 
selection such as poly-reactive or auto-reactive clonotypes [43, 55]. Whether the naïve B 
cell repertoire in HIV-1-infected individuals more frequently display features associated 
with poly- or self-reactivity is not known but will be important to investigate, especially in 
relation to the generation of broadly neutralizing antibodies (bNAbs) [193].  
Antigen-experienced cells. HIV-1-infected individuals also display alterations of the 
memory B cell compartment. Activated human memory B cells and tissue-like memory B 
cells are increased during persistent HIV-1 infection, whereas resting memory B cells are 
decreased in frequency [181, 194]. Already early on during HIV-1 infection these 
alternations in B cell compartments lead to consequences in the form of poor maintenance 
of serological antibody levels to previous vaccination (i.e. measles, tetanus and 
pneumococcus) [185], as well as impaired responses to new vaccinations [195]. Exhausted 
B cells also appear during the chronic phase of the infection. These exhausted B cells are 
characterized by a decreased capacity to proliferate in response to stimulation [196] and 
with expression of molecules that negatively regulate antigen receptor signaling or homing 
to sites of inflammation [197, 198]. Further, HIV-1-infected individuals display increased 
frequencies of circulating plasmablasts [199] consistent with non-antigen-specific 
differentiation of memory B cells into ASCs resulting in hypergammaglobulinemia and 
decreased numbers of resting memory B cells. Thus, the immune system in chronically 
HIV-1-infected individuals is different from that of healthy subjects in several ways, which 
likely affects the kinds of antibodies that are elicited. 
1.3.3.2 Non-neutralizing antibodies 
A majority of Env-specific antibodies generated during infection exhibit no neutralizing 
capacity. These non-neutralizing antibodies are the first Env-specific antibodies to be 
generated after acute HIV-1 infection. They appear during the first weeks of infection and are 
directed to non-functional forms of Env, as the unstable Env disassociates, resulting in expose 
of structures that would not be recognized on a closed native Env structure [147, 200]. As 
these antibodies lack neutralizing activity they do not have any impact on selective pressure 
of the virus, nor the viral load in plasma [201, 202]. 
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1.3.3.3 Strain-specific antibodies 
Strain-specific antibodies, also known as autologous antibodies, appear after a few months 
after infection. These antibodies are mostly directed against the highly variable and 
immunogenic regions of Env [203], which constantly mutate to escape the antibodies 
generated [204]. As a result of this, strain-specific antibodies are only capable of neutralizing 
the virus it was elicited for (the autologous virus) and not for any other viral variants that 
arose later [159, 167, 205]. 
1.3.3.4 Broadly neutralizing antibodies 
Eventually, after years of chronic HIV-1 infection (approximately 2-4 years), around 20% of 
infected individuals develop antibodies that are cross-neutralizing and 1-2% develop 
antibodies that are capable of neutralizing a broad range of HIV-1 strains [206, 207]. These, 
so called, bNAbs are rare [208] and so far, despite many HIV-1 vaccine clinical trials no 
vaccine candidate, nor any experimental vaccine candidate tested in animal models have been 
able to induce such antibodies in small animals or primates with natural immune systems. 
There are several distinct features that differ between bNAbs and those generated during Env 
immunization studies. These features include extremely high levels of SHM, long HCDR3 
regions, N-glycan recognition as well as, for some classes of antibodies, restricted V gene 
germline use [169, 170, 209, 210]. Although HIV-1 is highly variable, there are some 
determinants that are too important for the function of the virus to tolerate mutations, as 
previously described. These determinants are therefore the main targets for vaccine-induced 
antibodies and include the CD4bs, some V2 determinants in the trimer apex, the base of the 
V3 region including the “high mannose patch” and the interface region of gp120-gp41 [211]. 
N-glycan recognition of antibodies is uncommon in healthy individuals [212] as it is a sign of 
self-recognition. As chronic HIV-1 infection results in alternations in B cell populations, this 
might lead to that some B cells overcome the peripheral negative selection and hence express 
self-reactive properties [213]. The high degree of SHM in bNAbs are most likely a result of 
persisting antigen exposure in HIV-1 infected individuals, which drive B cells to undergo 
multiple rounds of affinity maturation and selection in the GC [168, 209, 214]. 
Due to the disease progression and establishment of extensive viral reservoirs that are the 
source of escape variants, it appears that bNAbs generated late during infection do not have 
any beneficial effect in the individual in which they arose. Instead, the value of bNAbs, if 
they could be induced by immunization, would be to provide protection prior to virus 
exposure (prophylactic vaccination). Such protective capacity of bNAbs has been 
demonstrated in passive immunizations studies in non-human primates (NHPs) where bNAbs 
were administered prior to SHIV infection [215-222].  
1.3.4 The envelope glycoprotein and immunogen design 
As described earlier, Env is the sole viral surface protein and hence the only available 
antibody target. Thus, Env is the main focus for a protein based vaccine against HIV-1. One 
of the major focuses within the HIV-1 immunogen design field is to engineer recombinant 
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native-like trimeric Env that expose as few non-neutralizing epitopes as possible to direct the 
induced immune response towards the desired neutralizing epitopes. The development of 
native-like trimeric Env can be divided into to two separate phases, early and new generation 
Env trimer mimetics, based on technical advances and increased knowledge. 
1.3.4.1 Early generation Env trimer mimetics 
In the early days of Env engineering, a stop codon was introduced to create soluble oligomers 
of Env. This stop codon was introduced at the C-terminus of the gp41 ectodomain just above 
the transmembrane domain. The problem with this approach was that the resulting Env 
immunogens were unstable due to the non-covalent association of gp120 and gp41 (reviewed 
in [223]). To improve this, the cleavage site of the gp160 precursor was deleted or mutated. 
This improved the stability of gp120 and gp41 association, but as it is a non-natural covalent 
association it created a mixture of gp140 conformations. The next step was to introduce a 
trimerization motif to make more stable and homogeneous trimers. The trimerization motifs 
included, for example, GCN4 or foldon [224-226]. As new methods were developed to study 
protein structural conformations, it became obvious that these Env trimers were also 
heterogeneous and did not assemble into a closed native-like conformation and hence they 
did not mimic the native functional Env trimers [227]. Nevertheless, despite the non-native 
conformation of these first generation Env trimers, they have contributed extensively to our 
knowledge of Env-specific B cell responses in immunization settings.  
 
Figure 3. Examples of early and new generation Env trimers. Illustration by Martina Soldemo. 
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1.3.4.2 New generation Env trimer mimetics 
One approach to generate stable trimers is to introduce one additional C residue each in 
specific residues of gp120 and gp41, resulting in a covalent link between the subunits but 
maintaining the natural gp120-gp41 cleavage site. This link is referred to as the SOS (501C to 
604C) disulfide bond [228]. However, this modification alone generated only a small fraction 
of well-folded stable trimers. The reason for this is the spring-loaded nature of gp41 to adopt 
a post-fusion configuration. This tendency to go from the pre-fusion state to the post-fusion 
state made it challenging to increase the stability of the Env trimers. The solution for this was 
to introduce an amino acid substitution in gp41 (an I559P) in the SOS Env trimer structure, 
which created the SOSIP Env trimer [229]. An additional modification was to introduce a 
truncation at residue 664 on the clade A BG505 strain background, resulting in high yield of 
homologous trimers after purification as documented via negative-stain electron microscopy 
(NS EM). The BG505 virus strain was selected after screening over 50 different Env 
constructs [230], demonstrating that Env from different HIV-1 strains are differently prone to 
generate stable trimers. So far, BG505.664 is the Env that naturally shows the most favorable 
conformation in terms of mimicking the native Env trimer [230, 231]. 
Another type of new generation native-like trimers is the uncleaved native flexibly linked 
(NFL) trimers [232] that contain a flexible-linker of 10 residues (G4S)2 between the C-
terminus of gp120 and N-terminus of gp41. When the NFL trimers were made on the BG505 
background they formed well-ordered trimers consistent with that this strain has properties 
that are favorable for the formation of soluble trimers. When Env sequences from other 
strains are used the NFL trimers produced after transient transfection contains not only well-
ordered trimers, but also aggregates, dimers and monomers. Additional selection steps are 
therefore needed to enrich for well-ordered trimers, were either bNAbs or non-NAbs are used 
for positive or negative selection, respectively [233, 234]. To increase the yield of well-
ordered trimers further design optimizations were performed by identifying amino acid 
residues from the BG505 SOSIP structure that increase the propensity of Env to form well-
ordered trimers, the so-called trimer derived (TD) mutations, and transferring these mutations 
to other Env strains [235]. Introduction of the 8 TD substitutions in the 16055 Env sequence 
generated mostly well-ordered trimers as determined by both size-exclusive chromatography 
(SEC) and EM. To stabilize the trimers in the pre-receptor bound confirmation, a cysteine-
pair was also introduced into the 16055 NFL TD sequence in the bridging region (CC=201-
433) to generate disulfide linkage to abolish the capacity of the trimers to undergo CD4-
induced conformational changes that normally occurs when gp120 binds CD4 resulting in a 
trimer construct referred to as 16055 NFL TD CC [235]. 
Current strategies to evaluate the conformation of recombinant soluble Env trimers include 1) 
the use of both bNAbs and non-Nabs, where only the former recognize native Env trimer 
structures, 2) differential scanning calorimetry (DSC) to measure a single homogeneous 
melting temperature, and 3) EM to determine the well-ordered native-like trimer [232, 233, 
235].  
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1.3.4.3 Particulate display 
The immune system has evolved to recognize pathogens such as viruses, which are 
considerably larger than soluble proteins. In addition, many viruses display their surface 
antigens in a multi-valent manner, which may lower the threshold for B cell activation due to 
the capacity of such antigens to cross-link the BCR. Thus, it is logical to speculate that 
improved immunogenicity may be achieved if Env could be displayed as multi-valent arrays 
on some sort of particle. HIV-1 naturally has a low Env spike density as described above and 
the generation of HIV-1-based virus-like particles (VPLs) with sufficient amount on Env on 
their surface has been challenging. HIV-1 also has non-functional forms of Env on its 
surface. Since such forms are undesired in a vaccine context this has hampered the 
development of HIV-1-based VLPs as vaccine candidates. One way to enrich for functional 
Env spikes on VLPs is to use protease-mediated degradation of the non-functional Envs on 
the virion surface [236]. A strategy to develop solid-phase proteoliposomes containing native 
Env trimers in a physiologic membrane setting was also explored [237] but this was met with 
similar problems as HIV-1-based VLPs in terms of low density of Env per particle [238]. A 
strategy to improve VPLs is to through the concept of intrastructural help (ISH) where non-
Env T helper epitopes are delivered together with Env to APCs to enhance the Env-specific T 
cell response ([239] and reviewed in [240]). An additional approach to present Env in a 
particulate manner is to couple Env at high density to synthetic liposomes [241]. One recent 
study from our laboratory evaluated the immunogenicity of soluble 16055 Env NFL trimers 
compared to the same trimers arrayed on liposomes in rhesus macaques and demonstrated 
that the latter induced improved neutralizing antibody responses against the autologous tier 2 
virus [242].  
1.3.5 The use of animal models in HIV-1 research 
The use of animal models in medical research is critical for our understanding of biological 
processes such as infectious diseases, immunology, neurology, pathology and toxicology. 
Information generated from animal experiments has been fundamental when, for example, 
developing new vaccines, new surgery methods and designing new treatments. All 
achievements in the medical field are a combination of animal experiments and new cell and 
tissue culture techniques as well as statistical analysis and new high through-put genomic 
screening. Despite the need of animal experiments to drive the medical research forward, 
animal studies shall be performed according to the “3 R’s” principle, namely to reduce the 
number of animals needed, to refine tests used and to replace the use of animals whenever 
possible. This principle, which was first published in 1959 by Russell and Burch as “The 
Principles of Humane Experimental Techniques”, has since been embedded worldwide in 
legislations governing research in animal models. 
1.3.5.1 Non-human primates 
Non-human primates (NHPs), especially the Asian macaques and particularly rhesus 
macaques, are frequently used to model HIV-1 infection since they can be infected with SIV 
and chimeric SIV/HIV (SHIV) viruses [243]. The level of homology between rhesus 
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macaques and humans is high both in sequence (93%) [244], gene expression pattern [245] 
and immune cell composition [246, 247]. Our group also showed that there is a high 
homology in antibody V gene segments between humans and rhesus macaques [248, 249], 
but a higher variability between individual macaques than between humans [250]. 
Traditionally, NHPs were used primarily to evaluate serum antibody responses induced by 
vaccination since reagents and protocols for cell-based assays were poorly developed for 
NHPs. Over the past decade our group has established methodology to analyze macaque B 
cell populations [251-253] and to single cell sort macaque memory B cells for monoclonal 
antibody isolation [242, 249, 254, 255] opening up new possibilities for vaccine research in 
the NHP model.  
1.3.5.2 Mouse strains 
Studies in mice investigating immune responses to non-pathogen-derived antigens, such as 
hen egg lysozyme (HEL) and the hapten-carrier antigen NP-CGG, have provided the 
foundation for our current understanding of lymphocyte development and host responses to 
antigens [62, 256-259]. There are clear benefits to using mice as an experimental model 
because of their short breeding cycles, the relatively low maintenance cost, the ease of 
generating genetically manipulated strains and the comprehensive genetic data bases 
available. However, mice have not been commonly used in the HIV-1 vaccine research field 
due to concerns that they do not mimic the human immune system sufficiently well. For 
example, it is known that many broadly neutralizing antibodies isolated from chronically 
HIV-1 infected humans have long D segments allowing the generation of antibodies with 
long HCDR3 regions, which may be required to access certain epitopes on Env. In contrast, 
mice encode short D segments, which may limit their capacity to generate antibodies capable 
of accessing epitopes such as the CD4bs on Env. Mice are extremely useful for basic 
immunological studies due to the many engineered strains available. The use of mice can 
therefore facilitate mechanistic studies to investigate specific questions regarding 
immunogenic properties of HIV-1 Env immunizations where challenge studies are not 
required. 
Various knock-in mouse systems are used trying to elicit certain classes of bNAbs. These 
knock-in (KI) mice are engineered systems compared to immunogenicity studies in animals 
with natural immune repertoire. As bNAbs are rare and it has been extremely challenging to 
even achieve heterologous HIV-1 specific antibodies in immunization studies, another 
approach has been recently developed. The question if it is possible to prime the right B cell 
precursor in an intact immune system by immunization has been raised. Germline-targeting 
immunogens have been used in genetically modified KI mice harboring BCRs with a HC of 
different bNAbs. This results in a hybrid BCR having human HC and mouse LC. By 
immunizing such mice, it was reviled that the antibody response elicited was selected for the 
B cell clones that had the suitable BCRs [260, 261]. The focus in this thesis has been to study 
immune responses to Env in mice with natural immune repertoire to ask fundamental 
immunological questions.  
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2 AIMS 
The overall aims of this thesis were to improve our understanding of antibody responses 
elicited by immunizations with recombinant HIV-1 Env trimers in mice, and to use different 
approaches to modulate the responses, thereby potentially improving the outcome of 
vaccination. 
The specific aim for each study was: 
Paper I: To investigate potential competition between B cells specific for distal epitopes 
on the same antigen. 
Paper II: To study if expanding the naïve B cell repertoire prior to immunization would 
improve the antibody responses to HIV-1 Env. 
Paper III: To establish flow cytometry-based protocols for studying Env-specific memory 
B cells and GC B cells in immunized mice. 
Paper IV: To evaluate how chemical cross-linking of HIV-1 Env to stabilize the trimer 
would influence the elicited immune responses. 
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3 MATERIALS AND METHODS 
3.1 ANIMALS 
Male or female mice, 7-9 weeks old at the beginning of each experiment, of both BALB/c 
and C57BL/6 strain were used (see respective paper for specific details for origin of mice). 
During all studies included in this thesis, the mice were kept at the animal facility at the 
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. All experiments 
were pre-approved by the Committee for Animal Ethics (Stockholm, Sweden) and performed 
under approved conditions according to given guidelines.  
3.2 IMMUNIZATIONS AND TREATMENT OF MICE 
To study B cell responses against HIV-1 Env, mice were immunized (s.c. or i.p.) with 10 µg 
recombinant HIV-1 Env trimers (early or new generation trimers, depending on which study) 
in 10 µg AbISCO-100 (Isconova), also known as Matrix M-1 (Novavax), or ImjectÒAlum 
(Thermo Scientific/Pierce) adjuvant. The number of booster injections was one or two and 
the time interval between each one of the injections were dependent on study layout of the 
specific study. In Paper II, mice were pre-treated with injections of recombinant BLyS (10 
µg per injection) or PBS for control mice, for 10 consecutive days with i.p. injections before 
Env immunization. Mice were sacrificed by incubation in CO2 chamber followed by cervical 
dislocation. 
3.3 RECOMBINANT PROTEINS 
3.3.1 Recombinant human BLyS  
Recombinant human BLyS was provided by Human Genome Science (Rockville, MD). 
3.3.2 Production and purification of Env glycoproteins 
For immunizations in Paper I, II and III, recombinant soluble Env foldon gp140 trimers 
(gp140-F) based on the YU2 isolate of HIV-1 was used [226]. In Paper IV, mice were 
immunized with recombinant NFL TD CC Env trimer from the HIV-1 16055 isolate. For the 
B cell ELISpot assay, biotinylated versions of YU2 gp140-F were used, as previously 
described [177]. Env-specific B cells was detected in flow cytometry by using biotinylated 
YU2 gp140-F trimers (Paper III). 
YU2 gp140-F trimers for immunizations and the probes used for B cell differential ELISpot 
in Paper I-III (gp140-F-Avitag, gp120-F-Avitag, gp120-F-ΔV3-Avitag, gp120-F-ΔV1/2/3-
Avitag and gp120-F-ΔV 1/2-Avitag), were previously described in [177, 226]. The Avitag 
sequence (GLNDIFEAQKIEWHE) was added to allow site-specific biotinylation of the 
probes. A foldon trimerization motif and the histidine tag (His)6 was added upstream the 
biotinylation site. In Paper I, the YU2-derived gV3 Env trimer was designed as described in 
[262]. All YU2 Env proteins were produced transient transfection in FreeStyle HEK293F 
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suspension cells (Invitrogen) using the FreeStyle 293 expression system (Invitrogen). After 4-
5 days, supernatant was collected and spun at 3500xg to remove cells and cell debris. This 
was followed by sterile filtration through a 0.22 µM filter and dissolved EDTA-free protease 
inhibitor tablets (Roche) and penicillin-streptomycin (Invitrogen) was added to the 
supernatant. Env proteins were then purified in a two-step process. First, the supernatant was 
passed through a lentil-lectin column where the glycans of the proteins were captured inside 
the column. To remove unspecific binding, the column was washed extensively in washing 
buffer (PBS/0.5 M NaCl). The protein bound to the column was then eluted by adding 
elusion buffer (1 M methyl-a-D-mannopyranoside) and the flow through was saved for the 
next purification step. Second, the flow through containing protein obtained from lentil-lectin 
(GE Healthcare) column was the loaded to the second column, the nickel (His-tag) column. 
The His-tag expressed on each protein binds to the nickel in the column. After extensive 
washing in wash buffer (PBS, 40 mM imidazole (IM), 0.5 M NaCl, 200 mMPO4) the proteins 
were eluted by adding elution buffer (300 mM IM in PBS) to the column. The flow through 
was the concentrated by using Amicon 30-kDa cut-off centrifugation tubes (Millipore). 
Buffer exchange to PBS was performed be adding PBS to the concentrated protein during 
additional spins with the centrifugation tube. To verify that the proteins and probes have same 
conformation as previous batches, the proteins were checked for the recognition of several 
different HIV-1 mAbs (b12, 17b, 2G12 and 2F5) in a binding ELISA where new batches 
were compared older in-use batches. They were also analyzed with SDS-PAGE to avoid 
usage of degraded trimers. 
The 16055 NFL TD CC trimers (Paper IV) were produced as previously described [232, 
235]. Briefly, the trimers were expressed in 293F cells and then were isolated by affinity 
chromatography using GNL (Galanthus nivalis lectin-agarose; Vector Labs), followed by 
negative selection using the non-neutralizing mAbs, GE136, for antibody affinity 
chromatography, and purified by size exclusion chromatography (SEC) using SuperdexTM 
200 columns (GE Healthcare Life Sciences) to isolate the predominant trimeric fractions. 
One part of the purified proteins was subjected to chemical cross-linking as previously 
described [263]. Briefly, 0.5 mg/ml of trimer was fixed with 5 mM glutaraldehyde (GLA) 
(ACROS Organics) at room temperature for 5 min and then the reaction was quenched by 
excess 50 mM glycine, pH7.5. The fixed trimers were negatively selected by GE136 antibody 
affinity chromatography and re-isolated by SuperdexTM 200 column SEC. The thermal 
melting (Tm) temperature of the trimers was determined using a Microcal VP-Capillary DSC 
(Malvern). Briefly, trimers were diluted in PBS pH 7.4 to 0.25 mg/ml and scanned at a rate of 
1ÅC/min. Data collected were analyzed after buffer correction, normalization and baseline 
subtraction using the VP-Capillary DSC Automated data analysis software. 
3.3.3 Enzymatic biotinylation of probes and conjugation to fluorochromes 
For detection of Env-specific B cells by ELISpot analysis as well as in flow cytometry, the 
different Env probes were biotinylated. A biotin-ligase biotinylation kit (GeneCopia) was 
used for site-specific biotinylation of the Avitag sequence of each probe. The biotinylation 
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reaction was performed according to manufacturer’s instruction. Env trimers used to detect 
antigen-specific GC and memory B cells via flow cytometry had to be conjugated to 
allophycocyanin (APC). This APC-conjugation was performed according to manufacturer’s 
instruction. Briefly, a total of 5.3 µg (split into five incubations) Streptavidin, 
Allophycocyanin Conjugate (Invitrogen) was incubated at 4°C together with 10 µg Env 
trimers and PBS for 20 min. This process was repeated four times until all 5.3ug streptavidin-
APC had been added. The resulting APC-conjugated Env trimers were then ready to use. 
3.4 SINGLE CELL SUSPENSIONS OF LYMPHOID ORGANS AND IN VITRO 
STIMULATIONS 
3.4.1 Single cell preparations 
Single cell suspensions were performed on spleens, inguinal LNs (ingLNs) and BM (from 
two femurs and two tibias per mouse). Spleens and ingLNs single cells were obtained by 
passing the organs through a 70 µM nylon cell strainer and collected in complete RPMI 1640 
medium (containing 5% FBS, 50 µM 2-mercaptoethanol, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µM streptomycin). BM was rinsed with complete RPMI 1640 medium 
using a syringe and needle to force the medium through the BM. BM cells was then collected.  
Red blood cell lysis buffer (hypotonic ammonium chloride solution) was added to lyse the 
red blood cells (this step was not performed on ingLN cells) and the reaction was stopped by 
addition of PBS. After spinning down the samples, the dead cells were removed by filtering 
the remaining cells to a new tube. These cells were then collected in complete RPMI 1640 
medium and cell numbers were calculated with trypan blue stain using the automated cell 
counter Countess (Invitrogen) for further experiments. 
3.4.2 CD4+ T cell depletion 
To deplete CD4+ T cells (Paper IV), protocol from EasySep negative selection kit was 
followed (Stemcell Technologies). Briefly, splenocytes were incubated in normal rat serum 
(Stemcell Technologies) and biotinylated rat anti-mouse CD4 antibody (clone: RM4-5; BD 
Pharmingen) for 10 min and every third min the mixture was mixed. EasySep Streptavidin 
Rapid Sphere 50001 beads (Stemcell Technologies) were vortexed and added to the cell 
mixture at a concentration of 75 µl/ml of cell suspension. The tube was then inserted into a 
magnet and after 2.5 min the negative fraction was discarded and collected in a new tube. 
3.4.3 In vitro stimulation 
3.4.3.1 Mitogen stimulation of splenocytes 
To measure IgM production in supernatant of naïve mouse splenocytes, in Paper I, cells 
were incubated in complete RPMI 1640 medium in the presence or absence of of 2 mg/ml 
LPS (Sigma) for 5 days at 37°C in 5% CO2. Supernatants were harvested and cleared of 
debris by centrifugation. The IgM binding to antigen was measured by ELISA. 
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3.4.3.2 T cell stimulation with peptides and proteins 
In Paper I, splenocytes were stimulated by incubation with a pool of 15-mer peptides 
overlapping by 9 aa spanning all but the V3 region of the wt Ag (Env-V3), the V3 region 
(V3), PMA (10 ng/ml)/ionomycin (5 µM), or complete RPMI 1640 medium. After 1 hour 
(hr) of incubation, Brefeldin A was added to a working concentration of 10 µg/ml and the 
cells were incubated for another 5 hrs. Cells were then harvested for flow cytometric analysis. 
Protein stimulations have another incubation scheme. Splenocytes were stimulated with 0.5 
µg/ml wt or gV3 trimers and incubated for 2 hrs. Brefeldin A was added and the cells were 
harvested 15 hrs later for flow cytometric analysis. 
3.5 SEROLOGICAL ANALYSIS 
3.5.1 Env-specific IgG ELISA 
To detect Env-specific antibody responses in serum, ninety-six well high-protein-binding 
MaxiSorp (Nunc) plates were pre-coated (Papers III and IV) with 100 ng (1 µg/ml) 
Galanthus nivalis lectin (Sigma) diluted in PBS and incubated over-night (ON) at 4°C. Plates 
were then washed 6 times in washing buffer (PBS/0.05% Tween-20) followed by addition of 
150 µl blocking buffer (2% fat-free milk in PBS) and incubated for 1 hr in room temperature 
(RT). After incubation, the blocking buffer was removed from the plates and soluble proteins 
was added at a concentration of 200 µg (2 µg/ml) and let to incubate in RT for 2 hrs.  
In Papers I and II, plates were coated with 100 µl soluble proteins or peptides spanning the 
V3 region at a concentration of 100 or 200 ng/well diluted in PBS. The plates were incubated 
ON at 4°C. After the incubation, plates were washed in washing buffer (PBS/0.05% Tween-
20) followed by addition of blocking buffer (2% fat-free milk in PBS). Plates were blocked 
for 1.5 h in RT. 
Plates were then washed 6 times in washing buffer to remove access protein coat followed by 
another incubation of blocking buffer for 1 hr. Before sera from immunized mice were added 
to plates, blocking buffer was removed and replaced with new blocking buffer. Serum was 
added in 3-fold or 5-fold serial dilution series starting at a concentration of 1:25 and 
incubated for 2 hrs in RT. In Paper I, human-derived mAbs (b12, VCR01, F105, 48D, 447-
52D and 39F) were added instead of serum at different concentrations. After washing the 
plates 6 times in washing buffer, secondary antibody diluted in PBS was added to each well. 
For total Env-specific and V3-specfic ELISA, the secondary antibody goat anti-mouse IgG-
horse radish peroxidase (HRP) (Southern Biotech) was used at a concentration of 1:1000. For 
isotype-specific Env serum antibody detection, goat anti-mouse IgG1-HRP (Southern 
Biotech) diluted 1:5000, goat anti-mouse IgG2a-HRP (Southern Biotech) diluted 1:5000, 
goat anti-mouse IgG2b-HRP (Southern Biotech) diluted 1:5000, goat anti-mouse IgG2c-HRP 
(Southern Biotech) diluted 1:5000 or goat anti-mouse IgG3-HRP (Southern Biotech) diluted 
1:1500 were added after dilution in PBS. Secondary antibodies were incubated in RT for 1 hr 
and removed by washing six times in washing buffer. To develop the plates, 100 µl of TMB 
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Stabilized Chromogen substrate (Invitrogen) or SigmaFAST OPD kit (Sigma-Aldrich) was 
added and incubated for 10 min in dark at RT. To stop the reaction 100 µl 1M H2SO4 was 
added to wells. The optical density (OD) was measured at 450 nm or 492 nm using an Asys 
Expert 96 ELISA reader (Biochrom). 
3.5.2 Total IgM and Env-specific IgM ELISA 
Total IgM levels were measured in serum (Paper II) by coating of 96-well ELISA plates 
(Nunc) with 100 µl polyclonal goat anti-mouse IgM (Southern Biotech) diluted to a 
concentration of 2 µg/ml in 0.05 M carbonate buffer. For Env-specific IgM ELISA (Paper I) 
plates were pre-coated with 200 ng/well of Env trimers. All plates were incubated ON at 4°C. 
The plates were the washed six times in washing buffer (PBS/ 0.05% Tween), followed by 
blocking for 1.5 hr in blocking buffer (PBS/ 5% FCS) at RT. After addition with fresh 
blocking buffer, serum was added and incubated for 2 hrs at RT. The plates were then washed 
six times in washing buffer and secondary anti-mouse IgM-ALP (Mabtech) or anti-mouse 
IgM-HRP (Southern Biotech) antibodies was added diluted in blocking buffer. After 1.5 h of 
incubation at RT the plates were washed six times in washing buffer. The ELISA plates were 
developed using either SIGMAFAST p-Nitrophenyl phosphate mix (Sigma-Aldrich), and the 
reaction was stopped by adding 3 N NaOH, or SureBlue TMB Microwell Peroxidase 
Substrate (KPL), and the reaction was stopped by adding TMB Stop Solution (KPL). The OD 
was measured at 405 or 450 nm, respectively, using an Asys Expert 96 ELISA reader 
(Biochrom). 
3.5.3 Anti-dsDNA IgM ELISA 
For detection of anti-dsDNA antibodies in Paper II, ELISA plates were pre-coated with 50 
µl met-BSA (Sigma-Aldrich) diluted to a concentration of 5 µg/ml in PBS and incubated for 
6 hrs at 4°C. After washing the plates four times in washing buffer (PBS/0.05% Tween) the 
plates were coated with 50 µl DNA (Sigma-Aldrich) diluted to a concentration of 50 µg/ml in 
PBS.  
For detection of anti-phosphorylcholine (PC) antibodies in Paper II, ELISA plates were 
coated with 50 µl PCBSA diluted to a concentration of 2.5 µg/ml in PBS at 4°C ON. The 
plates were then washed four times in washing buffer.  
Both sets of plates (anti-dsDNA and PC coated plates) were blocked in blocking buffer 
(PBS/1.5% BSA/0.1% gelatin/3 mM EDTA) for 2 hrs in RT. Fresh blocking buffer was then 
added to each well followed by addition of serum. The serum was incubated for 2 hrs in RT. 
Before addition of secondary antibodies, the plats were washed four times in washing buffer. 
Secondary antibodies, anti-mouse IgM-alkaline phosphatase (ALP) (Mabtech AB) or anti-
mouse IgM-HRP (Southern Biotech), were added in blocking buffer and incubated for 1 hr 
inRT. Depending on the secondary Ab used, the ELISA was developed using either 
SIGMAFAST p-Nitrophenyl phosphate mix (Sigma-Aldrich), and the reaction was stopped 
by adding 3 N NaOH, or SureBlue TMB Microwell Peroxidase Substrate (KPL), and the 
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reaction was stopped by adding TMB Stop Solution (KPL). The OD was measured at 405 or 
450 nm, respectively, using an Asys Expert 96 ELISA reader (Biochrom). 
3.5.4 Cardiolipin-specific IgM ELISA 
To measure cardiolipin in serum (Paper II), the 96-well ELISA plates (Nunc) were coated 
with 50 µl cardiolipin (Sigma-Aldrich) diluted to a concentration of 50 µg/ml in 99.5% 
EtOH. The coating content in the plates were allowed to evaporate completely at 4°C ON. 
The plates were blocked in in blocking buffer (PBS/ 10% FCS) for 1 h at 37°C. After the 
blocking, serum was added in fresh blocking buffer and incubated for 1 h at 37°C. The plates 
were then washed in PBS only. Secondary antibody anti-mouse IgM-HRP (Southern Biotech) 
was added in blocking buffer, and the plates were incubated for 1 h at 37°C. Before 
developing of the plates, they washed in PBS only. The development was performed with 
SIGMAFAST p-Nitrophenyl phosphate mix (Sigma-Aldrich), and the reaction was stopped 
by adding 3 N NaOH. The OD was measured at 405 nm, using an Asys Expert 96 ELISA 
reader (Biochrom). 
3.6 ELISPOT ASSAYS 
3.6.1 Differential B cell ELISpot 
To enumerate the Env-specific and total IgG ASCs the B cell ELISPOT assay was used 
(Papers I, II, III), as previously described [177]. Briefly, 96-well MultiScreen-IP filter plates 
(Millipore) were pre-treated with 70% ethanol and washed three times in sterile PBS before 
being coated with 1 µg/well (10 mg/ml) a polyclonal goat anti-mouse IgG antibody 
(Mabtech). The plates were incubated ON at 4°C. Two hours before addition of the cells, the 
plates were washed five times in sterile PBS and blocked with complete RPMI 1640 medium 
at 37°C for 2 hrs. Cells were added in duplicates to the wells in three-fold serial dilutions, 
starting at 106 cells/well. For in vitro stimulation of memory B cells (Paper II), splenocytes 
were cultured with or without 2 µg/ml LPS for 6 days. Cells from each culture were 
collected, transferred to ELISpot plates and wrapped in plastic wrap before the 12 hrs 
incubation at 37°C.  
The cells were removed by washing the plates six times in washing buffer (PBS/0.05% 
Tween-20) prior to the detection of spots. Total IgG-secreting cells were detected with 100 
ng/well (1 µg/ml) of a biotinylated polyclonal goat anti-mouse IgG (Mabtech AB) in 
blocking buffer (PBS/1% FCS/0.05% Tween-20). For the detection of Env-specific B cells, 
200 ng/well (2 µg/ml) of biotinylated protein (gp140-F-bio, gp120-F-bio, gp120-F-ΔV3-bio, 
gp120-F-ΔV1/2/3-bio and gp120-F-ΔV 1/2-bio or b-galactosidase as a control) was added 
diluted in blocking buffer and incubated for 2 hrs at RT. Plates were then washed six times in 
PBS before the addition of 100 µl ALP-conjugated streptavidin (Mabtech AB), diluted 
1:1000 in PBS. Plates were incubated for 45 min in RT and then washed six times in water. 
To develop the plates 100 µl of pre-filtered BCIP/NBT-plus substrate (Mabtech AB) was 
then added and incubated for 10 min at RT. Plates were washed extensively with tap water 
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and air-dried. Spots were counted in an ImmunoSpot analyzer (Cellular Technology). 
Memory B cell-derived ASCs were calculated by subtracting the background of non–LPS-
stimulated cultures from LPS-stimulated cultures. Env-specific ASCs were calculated as 
previously described [177]. 
3.6.2 T cell ELISpot 
3.6.2.1 Evaluation of CD4-specific T cell ELISpot 
To evaluate the specificity of the CD4+ T cell ELISpot assay (Paper IV), both total 
splenocytes and splenocytes lacking CD4+ cells due to depletion assay, were added to the 
ELISpot plates. The cytokines IFNg and IL-2 production of the two samples was measured. 
Everything else was performed accordingly to the T cell ELISpot protocol described in detail 
below. 
3.6.2.2 IFNg, IL-2 and IL-4 T cell ELISpot 
T cell ELISpot was performed to measure cytokine production after stimulation of total 
splenocytes, in Paper IV. First, 96-well Multiscreen-IP filter plates (Millipore) were pre-
treated with 70% ethanol, washed three times in PBS followed by coating with 5 µg/well (50 
µg/mL) of anti-mouse IFNg (mAb: AN18), anti-mouse IL-2 (mAb: 1A12) or anti-mouse IL-4 
(mAb: 11B11) all from Mabtech AB. Plates were incubated ON at 4°C. Before addition of 
splenocytes, the plates were washed six times followed by blocking with complete RPMI 
medium for 2 hrs at 37°C/5% CO2 in a humidified incubator. Splenocytes were the added to 
the wells at three different concentrations (200000, 100000 or 50000 cells) in a volume of 75 
µl and stimulated with one of the following stimuli; ConA (Sigma), NFL trimer (unfixed), 
NFL trimer (fixed) or medium alone. ConA was added at the final concentration of 2 µg/ml 
and NFL trimers at 6.67 µg/ml. Final volume in the wells was 150 µl. All stimuli were diluted 
in blocking buffer (PBS/0.05% Tween-20/1% FBS). The in vitro stimulation was incubated 
for 20 hrs at 37°C/5% CO2 in a humidified incubator. The cells were removed from the wells 
and plates were washed six times in washing buffer (PBS/0.05% Tween-20) before 
biotinylated secondary antibodies (Mabtech AB) were added. Anti-mouse IFNg (mAb: R4-
6A2), anti-mouse IL-2 (mAb: 5H4) and anti-mouse IL-4 (BV06-24G2) antibodies were 
added to corresponding wells at the working concentration 1 µg/ml. After incubation in RT 
for 2 hrs, plates were washed six times in PBS only and strepatividin-ALP (Mabtech AB) 
was diluted 1:1000, added to wells and incubated in RT for 45 min. Plates were the washed in 
water. To develop the plates, 100 µl of filtered BCIP/NBT plus substrate (Mabtech AB) was 
added to wells and incubated for 10 min in RT. To stop the reaction wells were emptied and 
washed extensively in tap water followed by air-drying. The spots were counted in an 
ImmunoSpot analyzer (CTL Immunospot). 
3.7 IMMUNOHISTOCHEMISTRY 
For immunohistochemistry staining of spleens (Paper II), a part of the spleen from each 
mouse was first immediately immersed in O.C.T. medium (Sakura) and snap-frozen in 2-
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methyl butane, which was kept cold in liquid nitrogen. The frozen sections were stored at -
80°C until further use. The spleens were cryo-sectioned (6-8 µm) onto SuperFrost Ultra Plus 
microscope slides (VWR). For GC structure staining the following antibodies was used: APC 
anti-B220 (RA3-6B2; eBioscience), biotinylated MOMA-1 (Abcam) and AlexaFluor488 
anti-TCRb (H57-597; Biolegend). Streptavidin conjugated Cy3 was used to visualized the 
biotinylated antibody. A Leica TCS SP5X, using a 10X/0.30 magnification objective (Leica 
506505 HCX FLUOTAR) was used to scan the sections. Leica Application Suite Advanced 
Fluorescence software was used to prepare images and ImageJ was used for final adjustment 
of brightness and contrast. 
3.8 HIV-1 PSEUDOVIRUS NEUTRALIZATION ASSAY 
Neutralization assays (Papers II and III) were kindly performed by the laboratory of John 
Mascola at the Vaccine Research Center at the NIH using a single round of infection HIV-1 
Env pseudovirus assay and TZM-bl target cells, as previously described [264]. Serum from 
individual mice were analyzed for neutralization against four tier 1 viruses (MN, HXBc2, 
SF162, and BaL) and one tier 2 virus (6535). The results were reported as the reciprocal of 
the serum dilution producing 50% virus neutralization, the serum neutralization ID50. For 
competition-neutralization assays, in Paper II, test or control ligand was added to the serum 
30 min prior to the addition of virus. V3-specific activation was mapped using a YU2-derived 
V3 peptide and a scrambled control peptide, as previously described [177, 265]. CD4bs-
directed neutralizing activity was mapped using a pair of probes referred to as TriMut and 
TriMut368/70 [266, 267]. 
3.9 FLOW CYTOMETRY 
3.9.1 Evaluation of binding antibodies 
To detect antigen binding to the primary receptor of HIV-1 Env (Paper I), wt or gV3 trimers 
were co-incubated with purified human CD4+ T cells for 30 min. The cells were then 
incubated with mAb 17b for an additional 30 min at 4°C, and antigen-antibody complexes 
bound to the cell surface were detected by flow cytometric analysis after the addition of 
FITC-conjugated anti-human IgG Ab (BD Pharmingen).  
3.9.2 Evaluation of splenocytes after CD4+ T cell depletion 
For control of successful CD4 depletion (Paper IV), CD4 depleted cell fraction and total 
splenocytes fractions were stained with CD3e-PE (145-2C11; eBioscience), CD8a-APC (53-
6.7; BD Pharmingen), CD4-FITC (H129.19; BD Pharmingen) and B220- PerCp Cy 5.5 
(RA3-6B2; BD Pharmingen) and incubated on ice for 20 min. The samples were washed, 
fixed with Cytofix solution (BD Pharmingen) and run on FACS Calibur cytometer (BD 
Bioscience).  
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3.9.3 Intracellular cytokine production after in vitro stimulation 
In Paper I, IL-2 and IFNg–producing CD4+ T cells were detected after in vitro stimulation 
(section 3.4.3.2) by incubation with FITC-conjugated anti-CD4 (BD Pharmingen) and PE-
conjugated anti-CD8 (BD Pharmingen) for 30 min at 4°C. This was followed by fixation and 
permeabilization of cells by Cytofix/Cytoperm, according to the manufacturer’s instructions 
(BD Biosciences). Antibodies specific for IL-2 and IFNg (APC-conjugated anti–IL-2 and 
PerCP-conjugated anti–IFNg), both from BD Bioscience, were incubated with the cells. 
Cytokine-producing cells were the collected and ran on a BD FACSCalibur, and data were 
analyzed using FlowJo software (TreeStar). 
3.9.4 Detection of Env-specific GC and memory B cells 
For detection of Env-specific GC and memory B cells (Paper III), samples were first 
incubated with Fc receptor block antibody (anti-CD16/32; BD Biosciences, San Diego, CA, 
USA) followed by addition of biotinylated Env protein pre-coupled to APC-conjugated 
streptavidin (Invitrogen). For detection of GC B cells, the following antibody panel was used: 
Pacific Blue anti-B220 (RA3-6B2), FITC anti-GL7 (GL7) and PerCP-Cy5.5 anti-IgD (11-
26c.2a). APC-conjugated streptavidin (Invitrogen) was added to visualize biotinylated Env 
proteins. All antibodies come from BioLegend except Live/dead AmCyan (Invitrogen). For 
detection of memory B cells, the following antibody panel was used: APC-eFluor780 anti-
B220 (RA3-6B2; eBioscience), FITC anti-IgD (11-26c; eBioscience), FITC anti-IgM 
(polyclonal; Southern Biotech) PE-Cy7 anti-CD38 (Biolegend). For detection of Env-specific 
GC B cells the samples were first incubated with Live/Dead AmCyan followed by addition of 
APC-conjugated Env protein for all samples except control samples. Stained cells were fixed 
in fixation buffer (BD Bioscience) and analyzed on a MoFlo™ XDP (Beckman Coulter) or 
LSRFortessa™ cytometer (BD Biosciences). Flow cytometry data were analyzed with 
FlowJo (TreeStar). 
3.9.5 Analysis of different B cell subsets after BLyS treatment 
In Paper II, single-cell suspensions from spleen and LN were stained with the following 
antibodies: PerCP anti-B220 (RA3-62B), biotinylated anti-CD23 (B2B4), PE anti- IgM (R6-
60.2), PE anti-CD95 (Jo2), allophycocyanin anti-CD8 (53-6.7) all from BD Biosciences, as 
well as APC anti-CD93 (AA4.1), Alexa Fluor 488 anti-GL7, PE anti-CD1d (1B1), PE anti-
CD3 PE (145-2C11) and FITC anti-CD4 (RM4-4), all from eBiosciences. Biotinylated 
antibodies were visualized with Alexa Fluor 488-conjugated streptavidin (Invitrogen). 
Stained cells were fixed in fixation buffer (BD Biosciences) and analyzed on a FACSCalibur 
(BD Biosciences). 
3.10  STATISTICAL ANALYSIS 
The data was analyzed with D’Agostino and Pearson omnibus normality test. If the data 
passed these tests, they were analyzed by unpaired, two-tailed Student´s t-tests; data that did 
not pass were analyzed by the Mann–Whitney U test or the Wilcoxon matched-pairs signed-
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rank test. Statistical analysis was performed using GraphPad Prism (GraphPad Software). 
Data were considered significant at *p=0.05, **p= 0.01, and ***p= 0.001. Statistical analysis 
was performed using GraphPad Prism V5.04 (GraphPad Software).  
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4 RESULTS AND DISCUSSION 
Throughout this thesis, I have studied antibody responses elicited by immunization with 
recombinant HIV-1 Env trimers in mice. In Paper I, II and III, I used the early generation 
YU2 gp140-F trimers while in Paper IV, I used the new generation 16055 NFL TD CC 
trimers. Several approaches were investigated to address basic questions in vaccine 
immunology.  
4.1 B CELL COMPETITION BETWEEN DISTAL EPITOPS ON COMPLEX 
ANTIGENS 
Most of the knowledge regarding antigen responses comes from studies in mice, where the 
majority of studies have used small antigens of non-pathogen origins, such as hen egg 
lysozyme (HEL) or hapten-carrier antigen NP-CGG. Often mice that were transgenic for the 
antigen of interest were used, i.e. mice expressing a single BCR specific for either HEL or 
NP. Less is known about B cell responses to complex, “real world” antigens, which are more 
relevant for infectious diseases, including how epitope-specific responses are regulated. In 
this regard, HIV-1 Env has proven to be a very useful model antigen as it is extremely well 
characterized with multiple immunogenic determinants and specific epitopes defined, thanks 
to the availability of structural information and many mAbs, allowing us to ask questions of 
basic immunological nature. 
4.1.1 Absent V3-specifc recognition of mAbs on gV3 trimer 
From previous work performed in our group [177], we have shown that a large proportion of 
the antibody response after three immunizations with the well-characterized YU2 Env foldon 
trimers [226] in mice was directed to the variable region 3 (V3). Since it is known that V3 is 
highly immunodominant, and therefore might distract or compete with responses toward 
more conserved epitopes that could result in bNAbs, we asked in Paper I whether B cells 
specific for different epitopes on Env compete during a vaccine-induced response. To test 
this, we designed a pair of isogenic soluble Env trimers where the only difference between 
them was their capacity to elicit antibodies against V3. By introducing three additional N-
linked glycosylation sites on each gp120 molecule of the trimers, the V3 region becomes 
masked by glycans. The trimers were designated as wildtype (wt) or gV3 (glycan masked 
V3). The antigenic properties of these trimers were characterized in Figure 1E by the 
recognition of six different HIV-1 specific monoclonal antibodies (mAbs). The mAbs tested 
were targeting the CD4bs (b12, VCR01 and F105), the CoRbs (48D) and the V3 region (447-
52D and 39F) of bith Env trimers. The only difference in mAbs binding was the lack of 
recognition of the V3-specific mAbs to gV3. 
4.1.2 Epitope-specific B cell responses  
The interest in understanding the sub-specificities generated after Env immunizations 
stimulated us to develop a differential B cell ELISpot assays capable of detecting ASCs 
eliciting antibodies directed to sub-regions on Env [177]. Compared to conventional B cell 
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ELISpot, our optimized approach gave both clearer spots and lower background staining. 
With this more sensitive ELISpot assay, a number of different probes were introduced in 
order to dissect the cellular immune response against different epitopes of this complex 
antigen. Briefly, the probes were lacking one or more regions. We used gp140-F trimers, 
gp120-F trimers, gp120-F-DV1/2 (lacking variable regions 1 and 2), gp120-F-DV3, gp120-F-
DV1/2/3 and gp120 monomers. By subtracting the number of ASCs recognizing one probe 
from another probe gives the difference in the number of ASCs between the probes. This 
gives information on how large the cellular response is against a certain region. 
We discussed two possible outcomes before the experiment started. We knew from a 
previous study [177] that the gp41 response dominated after two immunizations whereas V3-
specific responses only were a small portion of the total Env response and we also knew that 
this distribution changes after an additional immunization. After three immunizations, the 
V3-induced response takes up approximately 40-60% of the total Env response. We 
hypothesized that after three immunization we would either see a redistribution of the 
antigen-specific response to other than V3 in gV3 immunized mice or if the V3 masking only 
would lower the total Env-specific response without any re-distribution. Although, we were 
interested in the V3-specific response we decided to measure the polyclonal cellular response 
after both two and three immunizations with the differential ELISpot. It could be possible that 
a potential re-distribution among gV3 immunized mice was detectable already after two 
immunizations. 
First, we enumerated the probe-specific responses. No differences in mice immunized twice 
with wt trimer or gV3 trimers was observed, except the slightly lower numbers of probe-
specific cells in gV3 immunized mice. When the mice were boosted, a significant difference 
was observed between the groups of mice. Significant differences between wt and gV3 
immunized mice were seen when investigating the gp140-F and gp120-F probe responses. 
Serological analysis with ELISA performed with two different coatings – wt or gV3 coat – 
indicated a difference in half-max binding titers when coated with wt protein. As no 
difference was seen in serum against gV3 protein, these data suggest that the difference are 
correlated to the V3-response. 
To analyze the differences in more detail, we took advantage of the possibility to analyze the 
data with the differential B cell ELISpot method. By subtractive analysis, we could analyze 
the ASCs directed to gp41, V1/2, V3 and “other” (all responses that were not gp41 nor 
V1/2/3 directed). The results from the region-specific responses show that after three 
immunizations, there was a significant difference in the V3-specific response between wt and 
gV3 immunized mice. The gV3 immunized mice did not elicit V3-specific antibodies as 
expected due to the induced glycan masking on V3. Interestingly, the lack of V3-reponses did 
not re-distribute to other regions of Env that could be detected using the method in this study.  
The conclusion in Paper I was that the V3-specific response detected after three 
immunizations did not out-compete other responses as no re-distribution to other epitopes on 
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the same antigen was seen in gV3 immunized mice. Thus, these data suggested that there was 
no competition between B cells specific for distal epitopes on the same antigen. 
4.2 MANIPULATION OF THE NAÏVE B CELL POPULATION TO IMPACT B 
CELL RESPONSES TO RECOMBINANT HIV-1 ENV PROTEIN 
BLyS plays a central role in B cell development, homeostasis and selection in the periphery. 
As mentioned previously, lack of BLyS leads to impaired populations of transitional and 
mature/naïve B cells [53, 54], whereas an overexpression results in B cell hyperplasia and 
signs of autoimmunity [43, 55]. It takes many years for the development of bNAbs in some 
chronically HIV-1 infected individuals. At this point, there is a dysregulation of B cell 
subsets, which is not seen in healthy individuals. Based on this, we asked (Paper II) if the 
treatment with recombinant exogenous BLyS would have any impact on generation of the 
specificities on Env-specific antibodies.  
4.2.1 Effects on immune cells after recombinant BLyS treatment 
First, we studied the impact of exogenous BLyS treatment in mice. The mice were injected 
with BLyS during 10 consecutive days before analysis on lymphocyte populations and B cell 
subtypes. BLyS treated mice were compared to control mice that had been injected with PBS 
during 10 consecutive days. The spleen size and weight increased in BLyS treated mice, 
which most likely is due to the increased number of B cells. The numbers of T2 and T3 B 
cells increased in numbers as well as the follicular and MZ B cell population, after BLyS 
treatment. The BLyS treatment did, however, not affect the overall architecture of GCs 
observed in confocal microscopy. We next wanted to study if BLyS treatment would rescue 
any self/autoreactive B cells. This was done by measuring if antibodies in serum had 
reactivity against dsDNA, phosphorylcholin (PC) and cardiolipin. The results indicated an 
increase of self-reactive antibodies in mice immunized with BLyS compared to control mice, 
which also showed some reactivity against these self-antigens. When comparing ratios 
between total IgM and self-antigen specific binding titers, no difference between the groups 
was detected. This indicates that exogenous treatment with BLyS does not induce an increase 
in self-reactive antibodies.  
4.2.2 Pre-treatment with BLyS does not affect the overall response to Env 
immunization 
Next, BLyS pre-treatment prior to Env immunization was investigated to analyze if any new 
naïve Env-specific B cells had been rescued during BLyS treatment and thereby could be part 
of the immunization responses initiated. At two separate time points (day 4 and 21) after the 
last immunization, mice were sacrificed and the GC B cell population size was first compared 
between BLyS and PBS treated mice. No difference in GC B cell populations was observed 
using flow cytometry. This suggests that GC formation is not sensitive to elevated BLyS 
levels. When comparing whether the BLyS treatment could have any impact on sub-regional 
Env responses using the differential B cell ELISpot, no differences was seen between the 
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groups at both time points in spleen and BM. The conclusion is that BLyS pre-treatment does 
not have any impact on the overall Env-induced B cell responses. 
4.2.3 Elevated neutralization capacity in mice pre-treated with BLyS 
When no differences were detected in Env-specific ASCs, we were interested in if the BLyS 
treatment could have any effect on the neutralization capacity in the serum antibodies. Sera 
were collected after second, third and fourth immunization. To study this, a standardized 
single-round of infections by HIV-1 Env pseudoviruses and TZM-bl target cells were used 
[264, 268]. The sera were tested against four tier 1 and one tier 2 viruses. The result showed 
some neutralization capacity in four mice pre-treated with BLyS after the second 
immunization, whereas PBS control mice showed non-neutralization capacity. The capacity 
to neutralize, especially against the tier 1 viruses, increased in both groups for each 
immunization dose, although, BLyS treated mice showed higher neutralization capacity as 
well as the ability to neutralize more viruses. 
As BLyS has an effect on the survival of transitional B cells [269, 270] and, hence, the 
selection of naïve B cell repertoire, one could speculate if this altered naïve B cell pool in 
BLyS pre-treated mice did effect the increased neutralization capacity in those mice. As 
BLyS has also been reported to affect the duration of the GC responses [271], it would be 
interesting to perform a more detailed study on how the recombinant BLyS treatment actually 
effect the naïve B cell repertoire. A follow-up study is planned in rhesus macaques in 
Micheal Cancro’s lab to determine if a similar effect of BLyS can be observed in primates. 
4.3 ENV-SPECIFIC GC B CELLS AND MEMORY B CELLS IN MICE 
Mouse studies in our lab were previously performed in BALB/c mice; however, most 
transgenic mouse strains are on the C57BL/6 background. Therefore, in Paper III, we 
compared the Env-specific B cell responses between BALB/c and C57BL/6 mouse strains. 
Having done so, we established protocols to detect different Env-specific B cell populations 
in C57BL/6 mice to allow future analysis and sorting such cells from Env immunized mice. 
4.3.1 Comparable Env-specific responses in BALB/c and C57BL/6 mice 
First, mice where immunized twice with Env (foldon trimers) with AbISCO-100 adjuvant. 
Samples were collected five days post the last immunization. In general, C57BL/6 mice had 
both lower Env-specific total IgG binding titers measured in ELISA and lower number of 
total IgG and Env-specific ASCs in B cell ELISpot. Apart from lower numbers observed in 
C57BL/6 mice, the two mouse strains behaved similar to Env immunizations. This made us 
confident to continue our studies to dissect Env-specific B cell responses in C57BL/6 mice. 
4.3.2 Flow cytometry optimization to detect Env-specific B cells 
Memory B cells were previously less well defined in mice compared to in humans with the 
exception of some recent studies [80]. In this thesis, I decided to only use the well accepted 
CD38 as memory B cell marker, since it is not fully understood if the newly described 
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markers are true memory B cell markers, if they represent different sub-populations of 
memory B cells or if they simply indicate memory B cells under maturation phases. For the 
detection of GC B cells the marker CD95 and GL7 was used, along with AA4.1 to exclude 
immature/naïve B cells. These markers have been used in previous experiments performed in 
our lab and they are also frequently used by others. To detect Env-specific memory B cells 
and GC B cells, mice were immunized with Env in adjuvant three times before detection of 
respective cell population. The individual mice differed quite a bit in the frequency of Env-
specific B cells but the frequency was higher than in the control mice, which showed little or 
non-antigen specific memory and GC B cells.  
Although these Env-specific GC and memory B cell populations are much smaller in mice 
compared to those detected in NHPs [249], these data still indicate that such B cell 
populations are possible to detect in mice. Staining panels, as those presented here, can be 
used for sorting either bulk Env-specific B cell populations or performing single-cell sorting 
for mAb cloning for further functional studies of vaccine-induced responses. Together with 
published protocols for antibody cloning from C57BL/6 mice [272, 273], these studies offer 
the possibility to define Env vaccine-induced responses in mice, which is of interest to 
evaluate responses in various C57BL/6-based strains where pathways of interest have been 
perturbed. 
4.4 THE IMPACT OF CHEMICAL CROSS-LINKING OF ENV TRIMERS 
Chemical fixation of viruses and antigens was used in many commercial vaccines with 
varying success. For RSV, the fixed vaccine was shown to be associated with a pathogenic 
Th2-biased response, and the vaccine was removed from the market [274-276]. GLA fixation 
of NFL trimers was previously investigated in guinea pigs, where the focus was on the 
neutralizing capacity of the induced response [263]. In Paper IV, we asked if GLA fixation 
affected other aspects of the Env-specific responses by comparing unfixed and fixed 16055 
NFL TD CC Env trimers in C57BL/6 mice. We showed that the thermostability of the GLA 
fixed Env protein was increased, consistent with a previous report using other Env trimers 
[263].  
4.4.1 GLA fixation impacts the isotype-specific Env antibody responses 
We next immunized mice three times with either unfixed or fixed NFL trimer with a four-
week interval. Serum was collected after the second and third immunization. First, the total 
IgG Env-specific antibody responses was measured. The binding titers in ELISA was tested 
against both Env trimer coatings. Overall, the Env-specific IgG titers were higher in mice 
immunized with unfixed trimers compared to those immunized with fixed trimers after two 
immunizations. This difference was much smaller after three immunizations and it was less 
marked when fixed Env protein was used for coating in the ELISA plates. One goal of fixate 
the NFL trimer is to avoid exposure of irrelevant epitopes that might be exposed in unfixed 
proteins. It is likely that the difference in total Env-specific binding titers represents 
specificities directed against irrelevant epitopes; however, this has yet to be tested. 
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To evaluate if the use of GLA fixed trimers has any impact of the isotype-specific Env 
antibody responses, an ELISA using antibodies against IgG1, IgG2b and IgG2c was used. A 
shift in isotype-specificity was observed between the groups of mice. Mice immunized with 
fixed trimers showed higher IgG1 titers and lower IgG2b and IgG2c than mice immunized 
with unfixed trimers. When comparing the ratio between the isotypes, there was a significant 
difference between IgG1/IgG2b as well as between IgG1/IgG2c. This suggests that there is a 
Th2 shift in the antibody response elicited after immunization with fixed trimers. 
4.4.2 CD4+ T cell cytokine responses were unaffected of GLA fixation 
As CD4+ T cells can influence the elicited antibody isotypes and subclasses, we stimulated 
splenocytes ex vivo with both unfixed and fixed Env proteins, separately, for 20 hrs, and the 
cytokine-production was measured in a T cell ELISpot assay. No significant was observed in 
the cytokine-production (IFNg, IL-2 and IL-4) between the groups of mice. As no difference 
was seen in the number of cytokine-secreting cells, this could indicate that the uptake and 
processing of the two NFL trimers appears similar and that GLA fixation does not negatively 
impact the activation of CD4+ T cells. It would, however, be interesting to compare the 
proteins in another assay, where more cytokines can be evaluated. By using a bead array 
based flow cytometry platform (BD Bioscience), it could be possible to detect any differences 
in cytokine-production in greater detail. 
A previous study performed in rabbits, showed a more potent neutralization capacity in 
animals immunized with GLA fixed Env trimers [277]. In the present study, we aimed to 
focus on other aspects of the B cell response than the neutralization capacity and we showed 
that there is a Th2 shift in the antibody serum response in mice immunized with fixed protein. 
This Th2 skewing was not detectable in the T cell level. 
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5 CONCLUDING REMARKS 
The overall aim of this thesis was to use biochemically defined HIV-1 Env trimers to 
investigate basic B cell questions of relevance for the HIV-1 vaccine field. By using Env 
trimers in mouse models we wished to provide a link between more basic B cell immunology 
and HIV-1 vaccine research. The HIV-1 vaccine research field moves forward rapidly, 
especially in regards to immunogen design and structural analysis. As a result, the 
recombinant HIV-1 Env trimers used in Paper I-III were an earlier generation design 
compared to the trimers used in Paper IV.  
The results in Paper I indicate that there is no competition between B cells that recognize 
distal epitopes on the same antigen. By masking the highly immunogenic V3, no re-
distribution of the antibody response to other determinants on Env was detected. Instead, an 
overall lower response was seen in mice immunized with glycan-masked Env compared to 
the response observed in mice immunized with the isogenic wt trimers. In Paper II, the aim 
was to manipulate the naïve B cell pool in order to investigate if this would alter the elicited 
neutralizing antibody response. Pre-treatment with recombinant BLyS resulted in an increase 
in the number of peripheral B cells and a shift the B cell subsets and improved neutralizing 
responses. To be able to define the specificities of the induced response in greater detail, a 
staining protocol for detection of Env-specific memory and GC B cells was performed in 
Paper III. The protocols described in this paper can be used for both bulk sorting of Env-
specific B cells as well as in a single-cell sorting for cloning and functional testin of the 
induced antibodies. In the last study, Paper IV, the new generation NFL trimers were used 
and we investigated if GLA fixation would impact the elicited Env-specific immune 
response. We observed a clear skewing of the Env-specific antibody isotype response toward 
a more Th2 response with an increased IgG1:IgG2b ratio, which merits further investigation.  
In conclusion, the work included in this thesis has increased our understanding about B cell 
responses elicited by immunization using a highly relevant real-world antigen, HIV-1 Env.  
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